<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Parkinsons Dis</journal-id><journal-id journal-id-type="publisher-id">JPD</journal-id><journal-title-group><journal-title>Journal of Parkinson's Disease</journal-title></journal-title-group><issn pub-type="ppub">1877-7171</issn><issn pub-type="epub">1877-718X</issn><issn-l>1877-7171</issn-l><publisher><publisher-name>IOS Press</publisher-name><publisher-loc>Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4927924</article-id><article-id pub-id-type="publisher-id">JPD150685</article-id><article-id pub-id-type="doi">10.3233/JPD-150685</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Concept of Prodromal Parkinson&#x02019;s Disease</article-title><alt-title alt-title-type="left-running-head">P. Mahlknecht et al.</alt-title><alt-title alt-title-type="right-running-head">The Concept of Prodromal Parkinson&#x02019;s Disease</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mahlknecht</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="aff" rid="aff2">b</xref></contrib><contrib contrib-type="author"><name><surname>Seppi</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="aff1">a</xref></contrib><contrib contrib-type="author"><name><surname>Poewe</surname><given-names>Werner</given-names></name><xref ref-type="aff" rid="aff1">a</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff id="aff1"><label>a</label>Department of Neurology, <institution>Medical University Innsbruck</institution>, <country>Austria</country></aff><aff id="aff2"><label>b</label>Sobell Department of Motor Neuroscience, <institution>UCL Institute of Neurology</institution>, London, <country>UK</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: O. Univ.-Prof. Werner Poewe, MD, Department of Neurology, Innsbruck Medical University, Anichstra&#x000df;e 35, 6020 Innsbruck, Austria. Tel.: +43 512 504 23850; Fax: +43 512 504 23852; E-mail: <email>werner.poewe@i-med.ac.at</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>17</day><month>10</month><year>2015</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2015</year></pub-date><volume>5</volume><issue>4</issue><fpage>681</fpage><lpage>697</lpage><permissions><copyright-statement>IOS Press and the authors. All rights reserved</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License</ext-link>, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Parkinson&#x02019;s disease (PD) is currently clinically defined by a set of cardinal motor features centred on the presence of bradykinesia and at least one additional motor symptom out of tremor, rigidity or postural instability. However, converging evidence from clinical, neuropathological, and imaging research suggests initiation of PD-specific pathology prior to appearance of these classical motor signs. This latent phase of neurodegeneration in PD is of particular relevance in relation to the development of disease-modifying or neuroprotective therapies which would require intervention at the earliest stages of disease. A key challenge in PD research, therefore, is to identify and validate markers for the preclinical and prodromal stages of the illness. Currently, several nonmotor symptoms have been associated with an increased risk to develop PD in otherwise healthy individuals and ongoing research is aimed at validating a variety of candidate PD biomarkers based on imaging, genetic, proteomic, or metabolomic signatures, supplemented by work on tissue markers accessible to minimally invasive biopsies. In fact, the recently defined MDS research criteria for prodromal PD have included combinations of risk and prodromal markers allowing to define target populations of future disease modification trials.</p></abstract><kwd-group><label>Keywords</label><kwd>Parkinson&#x02019;s disease (PD)</kwd><kwd>biomarker</kwd><kwd>early diagnosis</kwd><kwd>premotor PD</kwd><kwd>nonmotor symptoms (NMS)</kwd><kwd>neuroimaging</kwd><kwd>genetic and molecular biomarkers</kwd></kwd-group></article-meta></front><body><sec id="sec0005"><title>INTRODUCTION</title><p>Currently, the diagnosis of Parkinson&#x02019;s disease (PD) is anchored on clinical criteria, which require the presence of bradykinesia and at least one further motor symptom out of tremor, rigidity or postural instability [<xref rid="r1" ref-type="bibr">1</xref>] and pathological studies have shown a strong correlation between the extent of Lewy Body related cell loss in the Substantia Nigra (SN) and the severity of bradykinesia [<xref rid="r2" ref-type="bibr">2</xref>]. However, this clinico-pathological concept of PD is challenged by several lines of evidence: Firstly, it has been noted for more than 20 years that nigral cell loss and striatal dopamine depletion progress to an approximate threshold of at least 40% before the first appearance of clinically defining motor signs [<xref rid="r2" ref-type="bibr">2, 3</xref>]. Secondly, Braak and colleagues have proposed a staging scheme of PD pathology with initiation of &#x003b1;-synuclein pathology in the caudal brainstem and the olfactory bulb and subsequent spread to the midbrain and eventually the limbic and neocortex [<xref rid="r4" ref-type="bibr">4</xref>]. This hypothesis has been extended by multiple studies suggesting early involvement of the peripheral autonomic nervous system in PD [<xref rid="r5" ref-type="bibr">5, 6</xref>]. Thirdly, the hypothesis of extra-nigral or even peripheral onset of disease seems to converge with clinical studies showing that PD patients may experience a variety of nonmotor symptoms before the first appearance of classical motor signs [<xref rid="r7" ref-type="bibr">7&#x02013;9</xref>]. Indeed, hyposmia, constipation, depression and idiopathic REM Sleep Behaviour Disorder (RBD) have been shown to go along with a significantly increased risk to develop PD in otherwise healthy subjects in population-based or other cohort studies [<xref rid="r10" ref-type="bibr">10&#x02013;17</xref>]. Taken together, these findings clearly speak to the existence of a stage of PD where affected subjects may be asymptomatic (&#x02018;preclinical PD&#x02019;) or where they may present with a variety of nonmotor symptoms and/or subtle motor signs that do not meet current diagnostic criteria (&#x02018;prodromal PD&#x02019;) [<xref rid="r18" ref-type="bibr">18, 19</xref>] (<xref ref-type="table" rid="jpd-5-4-jpd150685-t001">Table&#x000a0;1</xref>). Taken by themselves, however, these prodromal features lack specificity and &#x02013;with the possible exception of RBD &#x02013;have poor predictive value for PD. The challenge is, therefore, to characterise and validate markers that would enhance specificity and positive predictivity for currently prediagnostic stages of the illness. Here we review the current evidence for potential markers of preclinical or prodromal PD including clinical motor and nonmotor symptoms, neuroimaging measures, genetic susceptibility factors as well as molecular and biopsy biomarkers.</p></sec><sec id="sec0010"><title>PREDIAGNOSTIC NIGROSTRIATAL DYSFUNCTION IN PD</title><sec id="sec0015"><title>Neuropathological evidence</title><p>Neuronal loss in the SN pars compacta (SNc) associated with Lewy Body pathology is the pathologic hallmark feature of sporadic PD [<xref rid="r20" ref-type="bibr">20</xref>]. The extent of nigrostriatal dopaminergic denervation has been shown to correlate with severity of classical motor features of PD, in particular bradykinesia and rigidity[<xref rid="r2" ref-type="bibr">2, 21</xref>]. Different from age-related physiological cell loss in the SNc estimated to be in the order of 4 to 5% per decade, attrition of SNc dopaminergic neurons in PD seems to follow an exponential curve with an estimated 45% loss in the first decade of disease [<xref rid="r3" ref-type="bibr">3</xref>]. Pathological studies have shown 40&#x02013;60 % threshold of cell loss in the SNc and 60&#x02013;70 % striatal dopaminergic depletion before the appearance of motor symptoms meeting current PD criteria and extrapolation of the curves suggested a prediagnostic phase of progressive nigral cell loss of 5 years [<xref rid="r2" ref-type="bibr">2, 3</xref>]. Interestingly, incidental Lewy bodies are found in brainstem nuclei in more than 10% of individuals free of PD above age 60 and several lines of evidence argue that they may indicate preclinical stages of PD pathology rather than a by-product of neuronal aging [<xref rid="r22" ref-type="bibr">22, 23</xref>]. Clinicopathological studies found reduced nigral cell counts to be associated with increasing signs of subtle motor impairment also in subjects without PD [<xref rid="r22" ref-type="bibr">22, 23</xref>]. Individuals with incidental Lewy bodies in the SN and locus coeruleus were found to have loss of neurons in these nuclei as well as loss of tyrosine hydroxylase-positive fibres both in the striatum and epicardial fat which was intermediate between PD and normal controls [<xref rid="r24" ref-type="bibr">24</xref>]. Incidental Lewy bodies are also associated with nonmotor signs typically found in PD such as hyposmia [<xref rid="r25" ref-type="bibr">25</xref>] or constipation [<xref rid="r26" ref-type="bibr">26</xref>], again arguing that their presence may represent a presymptomatic phase of PD.</p></sec><sec id="sec0020"><title>Nigrostriatal dysfunction in PET/SPECT</title><p>Nigrostriatal dopaminergic denervation can be shown using radiotracers that label presynaptic dopaminergic markers such as the striatal dopamine transporters (DAT) as routinely achieved with single-photon emission computed tomography (SPECT) or decarboxylase activity with <sup>18</sup>F-Dopa positron emission tomography (PET). DAT imaging is closely correlated with post mortem SN cell counts [<xref rid="r27" ref-type="bibr">27</xref>] as well as severity and duration of disease [<xref rid="r28" ref-type="bibr">28</xref>] and has therefore been considered not only as a surrogate marker for disease progression, but also as a risk marker for PD [<xref rid="r29" ref-type="bibr">29</xref>]. Also, <sup>18</sup>F-Dopa PET studies in PD patients have shown faster rates of tracer-uptake decline in earlier versus later disease stages and, in accordance with the pathological post-mortem studies, extrapolation of these exponential curves have led to estimates of prediagnostic PD of approximately 6 years[<xref rid="r30" ref-type="bibr">30&#x02013;32</xref>].</p></sec><sec id="sec0025"><title>Subtle motor impairment and risk for PD</title><p>It has been argued that compensatory mechanisms may effectively counteract nigrostriatal dysfunction at the onset of cellular dysfunction and decline of striatal dopamine, thus delaying the appearance of overt parkinsonism for many years [<xref rid="r33" ref-type="bibr">33, 34</xref>]. Although slight motor abnormalities such as reduced arm swing, changes in walking patterns, stiffness, tremor, or bradykinesia may precede clinical PD, such signs, captured by routine clinical assessment for parkinsonism [<xref rid="r35" ref-type="bibr">35</xref>], often referred to as subtle motor impairment or mild parkinsonian signs, may be found in as many as 40% of the elderly population [<xref rid="r36" ref-type="bibr">36, 37</xref>]. In several studies mild parkinsonian signs have been associated with both other PD risk markers as well as with an increased risk for incident PD itself [<xref rid="r16" ref-type="bibr">16, 37</xref>]. These signs, however, are quite unspecific in the general population. This may be different when motor tests are applied to enriched cohorts with an apriori increased risk for PD. Prospective studies in subjects with idiopathic RBD have shown that in those who converted to clinically defined PD, impaired motor performance was detected 6&#x02013;9 years before diagnosis using the Purdue Pegboard, alternate-t p and timed up-and-go test [<xref rid="r38" ref-type="bibr">38</xref>]. Similarly, a more recent study by the same group following 89 idiopathic RBD patients over ten years found a 3.9 fold risk to develop PD, dementia with Lewy-bodies (DLB) or multiple system atrophy (MSA) in those with subtle motor impairment at baseline [<xref rid="r14" ref-type="bibr">14</xref>]. Using accelerometry-based evaluation of gait and stance, two cross-sectional studies found altered gait variability [<xref rid="r39" ref-type="bibr">39</xref>], trunk acceleration and smoothness of sway [<xref rid="r40" ref-type="bibr">40</xref>] under challenging conditions in otherwise asymptomatic LRRK2 mutation carriers and subjects with hyperechogenicity of the SN. Noyce and colleagues used an algorithm based on an online survey to categorise participants according to their putative PDrisk [<xref rid="r41" ref-type="bibr">41</xref>] in the definition of their prospective PREDICT-PD study cohort [<xref rid="r42" ref-type="bibr">42</xref>]. In a cross-sectional baseline analysis, the 100 highest-risk participants had significantly reduced tapping speed in a novel computer keyboard-tapping task versus the 100 lowest-risk participants [<xref rid="r42" ref-type="bibr">42</xref>]. Quantifiable motor tests may therefore eventually become useful as a screening element to select at-risk subjects for further secondary screens with more specific tests like DAT imaging.</p></sec></sec><sec id="sec0030"><title>EARLY NONMOTOR SYMPTOMS AND THE CONCEPT OF PREMOTOR PD</title><p>It is now well recognized that nonmotor symptoms are an integral part of the clinical spectrum of the disease [<xref rid="r43" ref-type="bibr">43&#x02013;46</xref>] and may even antedate the clinical manifestation of cardinal motor features of PD by several years in a substantial proportion of patients[<xref rid="r7" ref-type="bibr">7&#x02013;9, 47</xref>] (<xref ref-type="table" rid="jpd-5-4-jpd150685-t002">Table&#x000a0;2</xref>). Considering Braak&#x02019;s hypothesis that PD pathology first starts in extranigral sites, particularly the olfactory system, lower brainstem and peripheral autonomic nervous system [<xref rid="r4" ref-type="bibr">4, 5, 48</xref>], it is intriguing to note that recent clinical studies have found certain nonmotor symptoms such as constipation, dream enacting behaviour, and smell-loss preceding the onset of first motor complaints into time periods that are longer before motor onset as compared to other nonmotor complaints [<xref rid="r7" ref-type="bibr">7, 9</xref>].</p><sec id="sec0035"><title>Hyposmia</title><p>Olfactory detection, identification or discrimination deficits have consistently been found in approximately 80% of patients with PD [<xref rid="r56" ref-type="bibr">56, 57</xref>]. Although many patients retrospectively report smell loss prior to noting the first motor problems [<xref rid="r7" ref-type="bibr">7, 9</xref>], to date there are only two population based studies that have investigated prospective risk for PD in relation to baseline smell function [<xref rid="r16" ref-type="bibr">16, 17</xref>]. In the Honolulu-Asia Aging study (HAAS), a large cohort of more than 2000 men of Japanese ancestry was prospectively followed for PD incidence with respect to baseline olfactory performance using the Brief Smell Identification Test (B-SIT) [<xref rid="r17" ref-type="bibr">17</xref>]. After adjustment for age and other potential confounders, the odds ratio for incident PD within four years in those with the lowest quartile of B-SIT scores at baseline was 5.2 and 3.1 in the second lowest quartile as compared with the top two quartiles. However, hyposmia was not associated with PD risk beyond four years. Intriguingly, a clinicopathologic study in a subsample from the HAAS, found an association of olfactory dysfunction with incidental Lewy bodies in the SN [<xref rid="r25" ref-type="bibr">25</xref>]. Likewise, the PRIPS study, a large population-based cohort study on risk factors for incident PD (see imaging biomarkers), found a relative risk ratio of 6.5 in hyposmic participants over 3 years [<xref rid="r16" ref-type="bibr">16</xref>]. More recently, several studies have addressed the potential of hyposmia as a risk marker for PD in subjects with increased apriori risk for PD. For example, two recent prospective cohort studies of idiopathic RBD patients found that baseline olfactory dysfunction predicted incident Lewy body disorders over 5 and more years of follow-up [<xref rid="r14" ref-type="bibr">14, 58</xref>].</p></sec><sec id="sec0040"><title>REM-sleep behavior disorder (RBD)</title><p>RBD is a parasomnia clinically characterized by dream-enacting behaviours related to loss of physiological atonia during REM-sleep [<xref rid="r59" ref-type="bibr">59</xref>]. The prevalence of idiopathic RBD in the population is not well defined as definite diagnosis requires polysomnography. A commonly cited figure of 0.4% , however, may well be an underestimate [<xref rid="r60" ref-type="bibr">60</xref>]. Indeed, when using two validated screening questionnaires in an elderly population-based sample of 476 subjects, we recently found a prevalence of probable RBD of 5&#x02013;8% in a Caucasian population aged &#x0003e;60 years [<xref rid="r61" ref-type="bibr">61</xref>]. In this particular cross sectional study, probable RBD was associated with multiple other nonmotor markers of PD, while polysomnography was not available. Idiopathic RBD is increasingly recognized as a harbinger of neurodegenerative diseases, including not only PD but also other synucleinopathies like DLB or MSA. Several follow-up studies have found that the majority of subjects with idiopathic RBD (&#x0003e;80%) will convert into one of these disorders &#x02013;most commonly PD or DLB - with extended follow-up over decades [<xref rid="r15" ref-type="bibr">15, 54, 62</xref>]. Two recent prospective cohort studies have further substantiated these observations. Postuma and colleagues collected follow-up data in a multicentre sample of 305 patients with idiopathic RBD over up to 6 years and found an overall conversion to neurodegenerative diseases of 33% [<xref rid="r63" ref-type="bibr">63</xref>], which was time-dependent at 15% after 2 years, 25% after 3 years, and 41% after 5 years. Conversion to PD or DLB was common (42% and 50% , respectively), while only 8% converted to MSA. Idiopathic RBD patient who converted over the observational period were older, more likely to report a family history of dementia, and more frequently endorsed autonomic and/or motor symptoms on questionnaires compared to those who remained disease free, whereas many baseline characteristics including caffeine and nicotine exposure were not different between these groups [<xref rid="r63" ref-type="bibr">63</xref>]. With the aid of thorough testing batteries, conversion from RBD to PD or PD Dementia/DLB appears to be more predictable. One recent prospective study in 89 idiopathic RBD patients found that smell identification loss (hazard ratio (HR) 2.8), abnormal colour vision (HR, 3.1), and subtle motor impairment (HR, 3.9), as well as advanced age (HR, 1.1) and non-use of anti-depressants (HR, 3.5) was associated with conversion to one of these synucleinopathies (including MSA) over the 7.5 year observational period.</p><p>Taken together, current evidence shows that RBD is the most specific among the different risk factors for PD (see <xref ref-type="table" rid="jpd-5-4-jpd150685-t002">Table&#x000a0;2</xref>) and RBD cohorts seem obvious candidates for future disease-prevention studies for PD. However, the median latency to conversion into clinically defined PD can be as long as 12 to 14 years [<xref rid="r15" ref-type="bibr">15, 54</xref>], seriously limiting the feasibility of such trials. Therefore, we recently investigated whether olfactory impairment can predict early conversion to PD or PDD/DLB among 35 idiopathic RBD patients prospectively followed over 5 years [<xref rid="r58" ref-type="bibr">58</xref>]. Indeed, abnormal baseline performance on the multidimensional SniffinSticks test assessing odour identification, odour discrimination, and olfactory threshold predicted conversion to a Lewy body disorder with an accuracy of 82.4% , and this was also true for poor performance on the identification subscore only. Based on the findings from this cohort, sample sizes for a hypothetical neuroprotection trial in RBD with conversion to a Lewy body disorders as an endpoint could be reduced by 74&#x02013;80% for a 5-year trial if idiopathic RBD patients were pretested for baseline olfactory dysfunction. For example, a total of 760 patients with idiopathic RBD versus 188 patients with idiopathic RBD and olfactory dysfunction would be required to have an 80% chance to detect a 30% decrease in the primary outcome measure of conversion to a Lewy body disease [<xref rid="r58" ref-type="bibr">58</xref>]. Similar data were also reported by Postuma et al. who found that by excluding idiopathic RBD subjects &#x0003c;55 years of age or using antidepressants reduced estimated sample sizes for 3-year neuroprotection trials with the same outcome measure by &#x02265;25% when further pretesting for olfactory dysfunction, impaired colour vision, or subtle motor impairment and by &#x02265;40% when using combinations of these markers [<xref rid="r14" ref-type="bibr">14</xref>].</p></sec><sec id="sec0045"><title>Constipation</title><p>Constipation is common in PD affecting 28&#x02013;61% of patients [<xref rid="r46" ref-type="bibr">46</xref>]. In the Honolulu-Asia Aging study men with bowel movement frequencies of less than once per day had a relative risk for incident PD of at least 2.7 compared to men with more frequent bowel function [<xref rid="r10" ref-type="bibr">10</xref>]. The brains of 245 subjects from this cohort were available for post-mortem examination and &#x02013;consistent with the above finding &#x02013;there was a significant association of constipation in life with the prevalence of incidental Lewy Bodies in the SN at post-mortem: 24.1% of those who had reported less than 1 bowel movement per day had this pathologic feature as compared to 6.5% of those with bowel movement frequencies of greater than 1 per day [<xref rid="r65" ref-type="bibr">65</xref>]. Interestingly, several studies have recently reported on findings of synuclein-immunostaining in the enteric nervous system of PD subjects using colonic biopsies providing a possible link between colonic dysmotility and synuclein-related neurodegeneration in PD [<xref rid="r65" ref-type="bibr">65, 66</xref>]. However, specificity for PD seems to be rather low (see below under tissue biomarkers).</p><p>Intriguing as these associations are, none of the nonmotor symptoms discussed above in themselves have sufficient specificity to qualify for screening for PD risk in the population. While sensitivity for future PD can be as high as 80% for features like hyposmia or constipation, their specificity is low [<xref rid="r47" ref-type="bibr">47</xref>]. Although specificity and predictive value of idiopathic RBD for PD risk are much higher, sensitivity is quite low. In addition, for low prevalence disorders like PD, by definition positive predictive values of any of the features discussed are small and would only be in the order of 50% even for markers of 99% specificity [<xref rid="r67" ref-type="bibr">67</xref>]. Therefore, future screening tools to narrow down at-risk populations for PD will likely require the use of multiple markers potentially including imaging and molecular biomarkers.</p></sec></sec><sec id="sec0050"><title>BIOMARKERS FOR PD</title><p>A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention [<xref rid="r68" ref-type="bibr">68</xref>]. Several candidate PD biomarkers have emerged over the years and some are already established as useful diagnostic markers, particularly those related to neuroimaging. There is also exciting progress in the field of genetic and other molecular markers and recently also of tissue markers that can be accessed through biopsies.</p><sec id="sec0055"><title>Imaging biomarkers</title><sec id="sec0060"><title>Radiotracer imaging</title><p>Among various imaging techniques, radiotracer-based functional imaging currently offers the highest degree of accuracy in the diagnostic work-up of patients with early PD [<xref rid="r29" ref-type="bibr">29</xref>]. Decreased nigrostriatal dopaminergic function is associated with nonmotor symptoms known to precede PD. In a prospective study of first-degree relatives of PD patients, individuals with an olfactory dysfunction showed a faster decline of DAT binding compared to individuals with normal olfactory function [<xref rid="r69" ref-type="bibr">69</xref>]. Moreover, 10% of hyposmic individuals, who also had abnormal DAT binding at baseline, developed PD at 2 years and this figure rose to 12.5% at 5 years of follow-up [<xref rid="r49" ref-type="bibr">49</xref>]. Another recent prospective study showed that idiopathic RBD patients exhibited decreased DAT binding and faster rates of DAT-binding decline compared to healthy controls [<xref rid="r70" ref-type="bibr">70</xref>]. After 3 years of follow-up, 15% of RBD patients, who also had the lowest DAT binding at baseline, had developed PD. As DAT imaging is invasive, time consuming, and expensive, it would not lend itself for primary screening purposes but rather as a secondary screen in enriched populations, such as those with nonmotor symptoms. A recent report on sequential biomarker assessment of population-based hyposmia screening in a first and DAT imaging in a second step - the Parkinson At-Risk Syndrome (PARS) study -reported decreased radiotracer binding using DAT-SPECT to be present in 11% of hyposmic compared with 1% of normosmic participants [<xref rid="r71" ref-type="bibr">71</xref>]. Also male sex and constipation were predictive for a DAT-deficit such that combining these three factors increased the percentage of subjects with a DAT deficit to 40% [<xref rid="r71" ref-type="bibr">71</xref>]. In contrast to DAT imaging assessing nigrostriatal function, which is an established imaging method in neurodegenerative parkinsonism, direct visualisation of the neuropathologic process i.e. &#x003b1;-synuclein deposition and related neurodegeneration is not yet possible. In analogy to the Pittsburgh compound-B, an <italic>in vivo</italic> A<italic>&#x003b2;</italic> ligand labeling amyloid depositions in Alzheimer&#x02019;s dementia, PET radiotracers specific for &#x003b1;-synuclein are beeing developed [<xref rid="r72" ref-type="bibr">72</xref>]. Longitudinal imaging of &#x003b1;-synuclein could particularly be relevant in the context of clinical neuroprotection-trials and serve as a surrogat outcome.</p></sec><sec id="sec0065"><title>Magnetic resonance imaging</title><p>There is limited information as to the potential of magnetic resonance imaging (MRI) to detect brain changes associated with PD risk or prodromal PD. Two studies in patients with idiopathic RBD found alterations in diffusivity measures in the tegmentum of the midbrain and the pontine reticular formation, regions involved in the generation of REM sleep [<xref rid="r73" ref-type="bibr">73, 74</xref>]. In a functional MRI study, asymptomatic subjects with a heterozygous Parkin and PINK1 mutation exhibited additional recruitment of supplementary motor areas as an expression of compensatory mechanisms [<xref rid="r34" ref-type="bibr">34</xref>]. In early PD significant alterations in various MRI diffusivity measures in the SN [<xref rid="r75" ref-type="bibr">75, 76</xref>], olfactory tract [<xref rid="r75" ref-type="bibr">75, 77</xref>] and cortex [<xref rid="r78" ref-type="bibr">78</xref>] were found compared with healthy controls at a field strength of 1.5 T and at a higher field strength of 3.0 T. Two studies reported a complete separation of early PD patients from controls using fractional anisotropy values in the caudal SN at 3.0 T [<xref rid="r76" ref-type="bibr">76</xref>] and in the olfactory tract at 1.5 T [<xref rid="r75" ref-type="bibr">75</xref>].</p><p>Using T2<sup>&#x000a0;*</sup>-weighted 7T MRI, a recent study described a hyperintense ovoid area within the dorsolateral border of the otherwise hypointense SN pars compacta consistent with nigrosome 1 in healthy controls [<xref rid="r79" ref-type="bibr">79</xref>]. The absence of this feature was highly sensitive and specific for PD. Intriguingly, the presence of this feature assessed with susceptibility weighted imaging (SWI) at 3T distinguished PD patients from healthy controls in another dataset of the same group [<xref rid="r80" ref-type="bibr">80</xref>] as well as in our own large cohort of patients with neurodegenerative parkinsonism [<xref rid="r81" ref-type="bibr">81</xref>], with a sensitivity and specificity of &#x0003e;90% , respectively (<xref ref-type="fig" rid="jpd-5-4-jpd150685-g001">Fig.&#x000a0;1</xref>). In the latter study also all included patients with MSA and PSP exhibited this imaging feature (i.e. sensitivity of 100%), indicating that visual assessment of dorsolateral nigral hyperintensity on high-field SWI scans may serve as a new simple diagnostic imaging marker for neurodegenerative parkinsonian disorders [<xref rid="r81" ref-type="bibr">81</xref>]. Future studies will have to elucidate whether these or other changes in MRI measures can be visualized in subjects exhibiting other PD risk markers and serve as biomarkers for the premotor stage of the illness.</p></sec><sec id="sec0070"><title>Transcranial sonography</title><p>Over the past 2 decades, there has been considerable interest in the use of transcranial sonography (TCS) in PD&#x02014; a method which is less expensive, time consuming and more widely available compared to radiotracer or MR imaging [<xref rid="r82" ref-type="bibr">82</xref>]. An enlarged echogenic area at the anatomical site of the SN in the mesencephalic scanning plane, termed SN-hyperechogenicity, has consistently been found in at least 82% of PD cases but only in up to 23% of healthy controls [<xref rid="r82" ref-type="bibr">82, 83</xref>] (<xref ref-type="fig" rid="jpd-5-4-jpd150685-g001">Fig.&#x000a0;1</xref>). In PD patients, the SN-echogenic sign is neither related to disease severity nor does it change over time [<xref rid="r82" ref-type="bibr">82, 84</xref>] and its longitudinal stability has also been reported in healty controls [<xref rid="r85" ref-type="bibr">85</xref>] and idiopathic RBD patients [<xref rid="r86" ref-type="bibr">86</xref>]. Although the pathophysiologic underpinnings of this echo feature are not entirely clear, histopathological studies have shown a relation of SN-echogenicity with an increased SN iron and ferritin content [<xref rid="r87" ref-type="bibr">87</xref>] as well as with decreased neuromelanin and microglial activation in the SN in healthy subjects [<xref rid="r88" ref-type="bibr">88</xref>]. Functional imaging studies demonstrated its association with a decreased <sup>18</sup>F-Dopa uptake in healthy controls and SN-hyperechogenicity may therefore represent a surrogate marker of an increased vulnerability of the nigrostriatal dopaminergic system [<xref rid="r87" ref-type="bibr">87, 89, 90</xref>]. Whether SN-hyperechogenicity issuitable as a preclinical risk marker for PD in healthy elderly populations has recently been investigated in the PRIPS (Prospective validation of risk markers for the development of parkinsonian syndromes) study, a large population-based cohort study with promising results. Data from the 3- and 5-year follow-up investigations revealed a 17- and 21-fold increased risk of developing clinically defined PD in subjects exhibitingSN-hyperechogenicity compared to those without this echo-signal [<xref rid="r16" ref-type="bibr">16, 91, 92</xref>]. Interestingly, in a subset of this cohort, SN-hyperechogenity has even been shown to increase the risk for incident mild parkisonian signs over 5 years by about 2-fold, which increased to a 3-fold risk when combined with hyposmia [<xref rid="r93" ref-type="bibr">93</xref>].</p><p>By combining the imaging modalities <sup>18</sup>F-Dopa PET, MRI, and TCS, one study found that putaminal <sup>18</sup>F-Dopa uptake and T2 relaxation times of the SN in control subjects with SN-hyperechogenicity were between the values of PD patients and controls without SN-hyperechogenicity [<xref rid="r90" ref-type="bibr">90</xref>]. A recent study assessed a set of biomarkers including SN-echognicity in symptomatic and asymptomatic LRRK2 G2019S mutation carriers as well as in patients with sporadic PD and healthy controls [<xref rid="r94" ref-type="bibr">94</xref>]. SN-hyperechogenicity was observed not only in approximately 95% of sporadic and genetic PD cases but also in 85% of asymptomatic LRRK2 G2019S mutation carriers as compared to 15% of healthy controls [<xref rid="r94" ref-type="bibr">94</xref>], further substantiating the concept of SN-hyperechogenicity as vulnerability marker of the nigrostriatal dopaminergicsystem.</p></sec></sec><sec id="sec0075"><title>Genetic biomarkers</title><p>The diagnosis of idiopathic PD has become more complex thought the discovery of Mendelian genes which cause monogenic forms of the disease such as autosomal dominant mutations in the SNCA, LRRK2 or VPS35 genes and autosomal recessive Parkin or PINK1 mutations. Taken together these account for a small percentage of PD cases seen in clinical practice, but asymptomatic carriers of dominant PD mutations like LRRK2 are obvious candidates when trying to study the preclinical phase of PD. In addition,several other genes have been identified which contribute to an increased risk for the sporadic form of thedisease [<xref rid="r95" ref-type="bibr">95</xref>]. Derived from careful clinical observations of parkinsonism in patients with Gaucher&#x02019;s disease and their relatives, heterozygous mutation in the glucocerebrosidase (GBA) gene has been found to associate with PD risk with an odds ratio of 5.4 [<xref rid="r96" ref-type="bibr">96</xref>]. Penetrance of this mutation seems to be high [<xref rid="r97" ref-type="bibr">97</xref>] and the prevalence of GBA mutations in PD populations has been between 3 and 20% in different studies, with the highest rates found in PD patients of Ashkenazi Jewish ancestry [<xref rid="r96" ref-type="bibr">96&#x02013;99</xref>]. Importantly, pathogenic GBA variants are found in 1&#x02013;3% of the population [<xref rid="r96" ref-type="bibr">96</xref>] and are associated with deterioration in clinical markers of PD consistent with prodromal PD [<xref rid="r99" ref-type="bibr">99</xref>]. A more recent discovery is the association of mutations in the GTP cyclohydrolase 1 gene, representing the most common cause of DOPA-responsive dystonia, with sporadic PD with an odds ratio of 7.5 [<xref rid="r100" ref-type="bibr">100</xref>]. Pathogenic variants of this gene, however, seem to be rather rare in the population. Many more common low-risk susceptibility variants in other loci have only recently been identified and confirmed in large meta-analysis of datasets from genome-wide association studies (GWAS) in PD (<xref ref-type="table" rid="jpd-5-4-jpd150685-t003">Table&#x000a0;3</xref>). Although the effects of single genetic susceptibility factors seem to be small with odds ratios for each locus ranging from 0.7 to 1.8, risk profile analysis showed substantial cumulative risk in a comparison of the highest and lowest quintiles of genetic risk with odds ratio of 2.5 (95% CI 2.2&#x02013;2.8) in one [<xref rid="r101" ref-type="bibr">101</xref>] and 3.3 (95% CI 2.6&#x02013;4.3) in a more recent study [<xref rid="r102" ref-type="bibr">102</xref>] (<xref ref-type="table" rid="jpd-5-4-jpd150685-t003">Table&#x000a0;3</xref>). Many of the reported genes such as SNCA and LRRK2 are also known to encode for key-player proteins in PD pathogenesis [<xref rid="r95" ref-type="bibr">95</xref>]. A dedicated online database has recently been created, where results of all published genetic association studies in PD and meta-analysis are freely available (<ext-link ext-link-type="uri" xlink:href="http://www.pdgene.org">http://www.pdgene.org</ext-link>) [<xref rid="r103" ref-type="bibr">103</xref>]. In addition, a polygenic risk score, consisting of small effect allels, has recently been identified in a discovery GWAS dataset and replicated in 3 independent GWAS datasets [<xref rid="r104" ref-type="bibr">104</xref>]. The average polygenic score in patients with an early disease age at onset was significantly higher than in those with a late age at onset [<xref rid="r104" ref-type="bibr">104</xref>], substantiating the hypothesis that accumulation of common polygenic alleles with relatively low effect sizes may considerably enhance overall PD risk and anticipate disease onset.</p><p>However, the true value of genetic risk scores (GRS) in the prediction of incident &#x02018;sporadic&#x02019; PD is currently unknown. A recent study combined a GRS from 30 genetic risk factors with other PD markers using stepwise logistic regression analysis to identify PD cases in the Parkinson Progression Marker Initiative (PPMI) cohort as a training dataset [<xref rid="r105" ref-type="bibr">105</xref>]. The final model included GRS, olfactory function, family history of PD, age, and sex and was associated with an excellent separation of PD cases from controls in 5 independent validation cohorts (AUCs &#x0003e;0.92) [<xref rid="r105" ref-type="bibr">105</xref>]. When looking at the single markers however, olfactory assessment was most responsible for the explained variance (63%), followed by the GRS (14%), family history (11%), sex (6%), and age (6%) underlining the importance of olfactory testing for clinical and research purposes. Future prospective studies will have to assess the true value of this or similar models for the identification of prodromal PD.</p></sec><sec id="sec0080"><title>Molecular biomarkers</title><p>In addition to the recent genomic discoveries, proteomic markers mostly assessed in the cerebrospinal fluid (CSF) are also subject of great research interest [<xref rid="r107" ref-type="bibr">107</xref>]. Alpha-synuclein-related parameters were investigated in CSF of PD patients and control populations, in some studies also in combination with DJ1 (<xref ref-type="table" rid="jpd-5-4-jpd150685-t004">Table&#x000a0;4</xref>). Results have been inconsistent, which may be due to various confounders, different methodologies used for specimen collection and analysis and due to a lack of standardized operating procedures [<xref rid="r108" ref-type="bibr">108</xref>]. The latter will change with prospective multicentre studies such as PPMI, where 400 newly diagnosed PD patients and 200 healthy controls are undergoing regular CSF and imaging marker assessments in an attempt to identify diagnostic and progression biomarkers [<xref rid="r109" ref-type="bibr">109</xref>], as well as premotor and genetic markers in recently added substudies. First results in a cross sectional analysis of a subset of the cohort showed lower levels of A<italic>&#x003b2;</italic>1-42, T-tau, P-tau181, &#x003b1;-synuclein, and T-tau/A<italic>&#x003b2;</italic>
<sub>1&#x000a0;-&#x000a0;42</sub> early drug naive PD patients compared with healthy controls with a marked overlap between groups [<xref rid="r110" ref-type="bibr">110</xref>]. Also, recent meta-analyses of total a-synuclein in the CSF have found decreased levels compared to healthy controls with, however, substantial overlap resulting in a suboptimal diagnostic accuracy with a good sensitivity of 88% but a poor specificity of 40% for PD [<xref rid="r111" ref-type="bibr">111, 112</xref>]. Evaluation of a-synuclein and DJ1 in the plasma has produced conflicting results and may be futile as erythrocytes are the greatest source of these proteins in the blood and the slightest degree of hemolysis considerably influences measurements [<xref rid="r113" ref-type="bibr">113</xref>]. Other proteins in the peripheral biofluids have been investigated: Using an unbiased proteomic screening approach, a recent study found 11 plasma proteins to be associated with age at PD onset [<xref rid="r114" ref-type="bibr">114</xref>]. Among those, low levels of apolipoprotein A1 (ApoA1), the main component of high density lipoproteins (HDL), correlated with earlier PD onset also in a replication cohort and were furthermore associated with greater putaminal DAT deficit among hyposmic subjects at risk for PD in the PARS cohort [<xref rid="r114" ref-type="bibr">114</xref>]. These results have been replicated by the same authors in other cohorts including a subset of the PPMI study, where the same direct association with age at disease onset has been found for HDL levels [<xref rid="r115" ref-type="bibr">115</xref>]. ApoA1/HDL would represent a particularly interesting PD risk marker, as it is potentially modifiable by drugs like statins. The latter study did, however, not adjust for cofounders of ApoA1/HDL levels such as statin use [<xref rid="r115" ref-type="bibr">115</xref>]. Moreover, studies on the influence of statins on PD risk have been conflicting with some showing a decreased risk [<xref rid="r116" ref-type="bibr">116</xref>] and others an increased risk for the disease among statin users [<xref rid="r117" ref-type="bibr">117</xref>], the latter being in line with evidence of high total cholesterol and/or low density lipoprotein as a protective factor against PD [<xref rid="r118" ref-type="bibr">118, 119</xref>]. Therefore, more experimental and longitudinal clinical and population-basedstudies, thoroughly adjusting for multiple confounders, are warranted before ApoA1/HDL elevating drugs may be tested in prospective clinical neuroprotectiontrials.</p><p>Although there are other recent promising advances in molecular biomarker research including the measurement of microRNAs in blood of PD and RBD patients significantly differing from healthy controls [<xref rid="r120" ref-type="bibr">120, 121</xref>], there is currently no molecular marker or combination of markers that could reliably show increased risk to develop PD. However, in Alzheimer&#x02019;s disease, which has a pioneering role in neurodegenerative disease research, such biomarkers have been developed and incorporated in diagnostic guidelines [<xref rid="r122" ref-type="bibr">122</xref>]. Given the rapidly advancing biochemical technologies, it is strongly hoped that a premotorbiochemical biomarkers can be discovered in PD-risk populations [<xref rid="r123" ref-type="bibr">123</xref>].</p></sec><sec id="sec0085"><title>Tissue biomarkers</title><p>The exact clinocopathological correlations underlying the various NMS in PD or pre-PD are still poorly defined. Orthostatic hypotension and constipation may well be mediated by cardio-sympathetic and vasomotor denervation as well as pathology in the enteric nervous system, respectively. Indeed, recent studies have provided consistent evidence for synuclein-related pathology in the peripheral autonomic nervous system using skin punch biopsies, biopsies of the salivary glands as well as colonic biopsies [<xref rid="r131" ref-type="bibr">131&#x02013;136</xref>]. Biopsy studies of synuclein immunostaing in colonic mucosa and submucosa in PD have produced inconsistent results with some authors reporting differences in the percentage of immunopositive samples in PD versus controls [<xref rid="r66" ref-type="bibr">66, 137, 138</xref>] and others finding no difference in the prevalence of synuclein-immunostaining of the enteric nervous system [<xref rid="r139" ref-type="bibr">139</xref>]. Differences between studies might be related to differences in tissue preparation, staining techniques and antibodies used [<xref rid="r136" ref-type="bibr">136</xref>]. For example a recent study only found possible differences between PD and controls when using antibodies againstphosphorylated &#x003b1;-synuclein [<xref rid="r140" ref-type="bibr">140</xref>], but this has again not been the case in another report [<xref rid="r139" ref-type="bibr">139</xref>]. In addition, synuclein immunopositivity may depend on the site of specimen collection with higher densities in the rostral as compared to caudal aspects of the gut [<xref rid="r136" ref-type="bibr">136</xref>]. A recent study found &#x003b1;-synuclein pathology also in the gastric mucosa of PD patients with a sensitivity of 85% and a specificity of 95% [<xref rid="r141" ref-type="bibr">141</xref>]. Interestingly, &#x003b1;-synuclein pathology was identified in some PD patients, in whom gut biopsies were taken up to 8 years prior to a clinical diagnosis of PD [<xref rid="r142" ref-type="bibr">142, 143</xref>] and one study has found positive immunostaining for phospho-synuclein in some individuals with RBD but in none of a group of age-matched controls [<xref rid="r140" ref-type="bibr">140</xref>]. The specificity of such findings for preclinical or prodromal PD still needs to be defined as there are studies strongly suggesting that &#x003b1;-synuclein is a normal constituent of nerve fibres and ganglionic cells in the enteric nervous system [<xref rid="r136" ref-type="bibr">136, 144</xref>]. Two studies have recently reported increased aggregation of phospho-synuclein and fibre loss in autonomic sudomotor and pilomotor fibres in skin punch biopsies in PD patients but not in healthy controls [<xref rid="r132" ref-type="bibr">132, 133</xref>]. Another region of potential specimen collection for the detection of peripheral &#x003b1;-synuclein may include the salivary glands; although biopsies of minor salivary glands largely lack&#x003b1;-synuclein depositis [<xref rid="r134" ref-type="bibr">134, 145</xref>], pre- and post-mortem studies using submandibular gland tissue have found phosphorylated &#x003b1;-synuclein in most PD cases [<xref rid="r134" ref-type="bibr">134</xref>]. While olfactory bulb &#x003b1;-synuclein is highly specific and sensitive for Lewy body disorders [<xref rid="r146" ref-type="bibr">146</xref>], a study using peripheral olfactory epithelium failed to detect &#x003b1;-synuclein [<xref rid="r147" ref-type="bibr">147</xref>]. Out of all &#x003b1;-synuclein related biopsy markers, specimen from the gastronintestinal tract and the salivary glands appear to be the most promising candidate tissue for detection of PD specific pathology [<xref rid="r136" ref-type="bibr">136</xref>].</p><p>Related to the findings of PD specific pathology in the gut, it seems important to mention that an altered gut microbiom has recently been identified by two studies in PD patients as compared to controls [<xref rid="r148" ref-type="bibr">148, 149</xref>]. A proinflammatory effect of the altered microbiosis has been suggested to trigger enteric synuclein-aggregation and subsequent spread of PD pathology [<xref rid="r149" ref-type="bibr">149, 150</xref>]. Further studies will have to look into potential relations and pathophysiological relevance of the microbiome in PD as well as its role for PD risk prediction.</p></sec></sec><sec id="sec0090"><title>OUTLOOK</title><p>There is now converging and compelling evidence for the existence of a latent phase of PD where disease specific molecular events of intracellular &#x003b1;-synuclein misfolding, oligomer and fibril formation are initiated to eventually cause neuronal dysfunction and cell death. For unknown periods of time this process may remain clinically asymptomatic (&#x02018;Preclinical PD&#x02019;) or may cause motor or nonmotor symptoms that are in themselves unspecific and do not meet current diagnostic criteria for PD (&#x02018;Prodromal &#x02018; PD). Recent experimental data strongly suggest that the evolution and clinical progression of PD may be largely driven by cell-to-cell propagation of pathogenic &#x003b1;-synuclein species in the central and also peripheral autonomic nervous system in a prion-like fashion [<xref rid="r151" ref-type="bibr">151, 152</xref>]. Therapeutic interventions should therefore ideally target the triggering pathogenic events as early as possible to achieve not only slowing of disease progression but also forestalling of disease onset. This makes early diagnosis a key priority and creates an urgent need for valid PD biomarkers with predictive validity for PD diagnosis. Until now several nonmotor clinical features have been shown to associate with PD risk and the combined occurrence of RBD and hyposmia in otherwise asymptomatic subjects has been shown to associate with the development of clinically defined PD or other Lewy body disorders in a substantial proportion over a relatively short time. While this makes RBD patients a realistic target population for future disease prevention studies of PD, it falls short of defining PD risk at the population level. Combinations of demographic, clinical, genetic and imaging markers have now been tested in large PD samples and also at the population level with promising results regarding diagnostic accuracy as well as definitions of PD risk. Searching for synuclein deposition in nervous tissue that can be obtained with minimal invasive procedures like colonoscopy or skin punch biopsies has so far yielded inconsistent results, but, if further refined, may open up another window into detecting preclinical PD pathology.</p><p>Taken together, current evidence strongly supports a paradigm shift in the diagnosis of PD with a new focus on defining prodromal stages of the disease. In fact, a task force of the International Parkinson and Movement Disorder Society (MDS) has very recently developed research criteria for the definition of prodromal PD by combining various risk and prodromal markers [<xref rid="r153" ref-type="bibr">153</xref>] with the ultimate goal of designing clinical trials to test interventions for disease prevention in at-risk individuals.</p></sec><sec id="sec0095"><title>CONFLICT OF INTEREST</title><p>The authors report no conflict of interest related to this manuscript.</p></sec></body><back><ref-list><title>References</title><ref id="r1"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gibb</surname><given-names>WR</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group>
<year>1988</year>
<article-title>The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson&#x02019;s disease</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<volume>51</volume>
<fpage>745</fpage>
<lpage>752</lpage>
<pub-id pub-id-type="pmid">2841426</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Greffard</surname><given-names>S</given-names></name><name><surname>Verny</surname><given-names>M</given-names></name><name><surname>Bonnet</surname><given-names>A-M</given-names></name><name><surname>Beinis</surname><given-names>J-Y</given-names></name><name><surname>Gallinari</surname><given-names>C</given-names></name><name><surname>Meaume</surname><given-names>S</given-names></name><name><surname>Piette</surname><given-names>F</given-names></name><name><surname>Hauw</surname><given-names>J-J</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name></person-group>
<year>2006</year>
<article-title>Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra</article-title>
<source>Arch Neurol</source>
<volume>63</volume>
<fpage>584</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="pmid">16606773</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fearnley</surname><given-names>JM</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group>
<year>1991</year>
<article-title>Ageing and Parkinson&#x02019;s disease: Substantia nigra regional selectivity</article-title>
<source>Brain</source>
<volume>114</volume>
<issue>Pt 5</issue>
<fpage>2283</fpage>
<lpage>2301</lpage>
<pub-id pub-id-type="pmid">1933245</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Bratzke</surname><given-names>H</given-names></name><name><surname>Hamm-Clement</surname><given-names>J</given-names></name><name><surname>Sandmann-Keil</surname><given-names>D</given-names></name><name><surname>R&#x000fc;b</surname><given-names>U</given-names></name></person-group>
<year>2002</year>
<article-title>Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson&#x02019;s disease (preclinical and clinical stages)</article-title>
<source>J Neurol</source>
<volume>249</volume>
<issue>Suppl</issue>
<comment>III/1-5</comment>
</element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name></person-group>
<year>2012</year>
<article-title>Lewy pathology and neurodegeneration in premotor Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>597</fpage>
<lpage>607</lpage>
<pub-id pub-id-type="pmid">22508278</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Fujishiro</surname><given-names>H</given-names></name><name><surname>Orr</surname><given-names>C</given-names></name><name><surname>DelleDonne</surname><given-names>A</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Frigerio</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>M</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Klos</surname><given-names>KJ</given-names></name><name><surname>Ahlskog</surname><given-names>JE</given-names></name></person-group>
<year>2009</year>
<article-title>Neuropathology of non-motor features of Parkinson disease</article-title>
<source>Parkinsonism Relat Disord</source>
<volume>15</volume>
<fpage>S1</fpage>
<lpage>S5</lpage>
<pub-id pub-id-type="pmid">20082965</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pont-Sunyer</surname><given-names>C</given-names></name><name><surname>Hotter</surname><given-names>A</given-names></name><name><surname>Gaig</surname><given-names>C</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Compta</surname><given-names>Y</given-names></name><name><surname>Katzenschlager</surname><given-names>R</given-names></name><name><surname>Mas</surname><given-names>N</given-names></name><name><surname>Hofeneder</surname><given-names>D</given-names></name><name><surname>Br&#x000fc;cke</surname><given-names>T</given-names></name><name><surname>Bay&#x000e9;s</surname><given-names>A</given-names></name><name><surname>Wenzel</surname><given-names>K</given-names></name><name><surname>Infante</surname><given-names>J</given-names></name><name><surname>Zach</surname><given-names>H</given-names></name><name><surname>Pirker</surname><given-names>W</given-names></name><name><surname>Posada</surname><given-names>IJ</given-names></name><name><surname>&#x000c1;lvarez</surname><given-names>R</given-names></name><name><surname>Ispierto</surname><given-names>L</given-names></name><name><surname>De F&#x000e1;bregues</surname><given-names>O</given-names></name><name><surname>Call&#x000e9;n</surname><given-names>A</given-names></name><name><surname>Palas&#x000ed;</surname><given-names>A</given-names></name><name><surname>Aguilar</surname><given-names>M</given-names></name><name><surname>Mart&#x000ed;</surname><given-names>MJ</given-names></name><name><surname>Valldeoriola</surname><given-names>F</given-names></name><name><surname>Salamero</surname><given-names>M</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name></person-group>
<year>2015</year>
<article-title>The onset of nonmotor symptoms in Parkinson&#x02019;s disease (The ONSET PDStudy)</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>229</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="pmid">25449044</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schrag</surname><given-names>A</given-names></name><name><surname>Horsfall</surname><given-names>L</given-names></name><name><surname>Walters</surname><given-names>K</given-names></name><name><surname>Noyce</surname><given-names>A</given-names></name><name><surname>Petersen</surname><given-names>I</given-names></name></person-group>
<year>2014</year>
<article-title>Prediagnostic presentations of Parkinson&#x02019;s disease in primary care: A case-control study</article-title>
<source>Lancet Neurol</source>
<volume>14</volume>
<fpage>57</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">25435387</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaenslen</surname><given-names>A</given-names></name><name><surname>Swid</surname><given-names>I</given-names></name><name><surname>Liepelt-Scarfone</surname><given-names>I</given-names></name><name><surname>Godau</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name></person-group>
<year>2011</year>
<article-title>The patients&#x02019; perception of prodromal symptoms before the initial diagnosis of Parkinson&#x02019;s disease</article-title>
<source>MovDisord</source>
<volume>26</volume>
<fpage>653</fpage>
<lpage>658</lpage>
</element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Masaki</surname><given-names>KH</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><name><surname>Grandinetti</surname><given-names>a</given-names></name><name><surname>Blanchette</surname><given-names>PL</given-names></name><name><surname>Popper</surname><given-names>JS</given-names></name><name><surname>Ross</surname><given-names>GW</given-names></name></person-group>
<year>2001</year>
<article-title>Frequency of bowel movements and the future risk of Parkinson&#x02019;s disease</article-title>
<source>Neurology</source>
<volume>57</volume>
<fpage>456</fpage>
<lpage>462</lpage>
<pub-id pub-id-type="pmid">11502913</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savica</surname><given-names>R</given-names></name><name><surname>Carlin</surname><given-names>JM</given-names></name><name><surname>Grossardt</surname><given-names>BR</given-names></name><name><surname>Bower</surname><given-names>JH</given-names></name><name><surname>Ahlskog</surname><given-names>JE</given-names></name><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>Bharucha</surname><given-names>AE</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name></person-group>
<year>2009</year>
<article-title>Medical records documentation of constipation preceding Parkinson disease: A case-control study</article-title>
<source>Neurology</source>
<volume>73</volume>
<fpage>1752</fpage>
<lpage>1758</lpage>
<pub-id pub-id-type="pmid">19933976</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishihara</surname><given-names>L</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group>
<year>2006</year>
<article-title>A systematic review of depression and mental illness preceding Parkinson&#x02019;s disease</article-title>
<source>Acta Neurol Scand</source>
<volume>113</volume>
<fpage>211</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="pmid">16542159</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shiba</surname><given-names>M</given-names></name><name><surname>Bower</surname><given-names>JH</given-names></name><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Peterson</surname><given-names>BJ</given-names></name><name><surname>Ahlskog</surname><given-names>JE</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name></person-group>
<year>2000</year>
<article-title>Anxiety disorders and depressive disorders preceding Parkinson&#x02019;s disease: A case-control study</article-title>
<source>Mov Disord</source>
<volume>15</volume>
<fpage>669</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="pmid">10928577</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Gagnon</surname><given-names>J-F</given-names></name><name><surname>Bertrand</surname><given-names>J-A</given-names></name><name><surname>G&#x000e9;nier Marchand</surname><given-names>D</given-names></name><name><surname>Montplaisir</surname><given-names>JY</given-names></name></person-group>
<year>2015</year>
<article-title>Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials</article-title>
<source>Neurology</source>
<volume>84</volume>
<fpage>1104</fpage>
<lpage>1113</lpage>
<pub-id pub-id-type="pmid">25681454</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Valldeoriola</surname><given-names>F</given-names></name><name><surname>Serradell</surname><given-names>M</given-names></name><name><surname>Sanchez-Valle</surname><given-names>R</given-names></name><name><surname>Vilaseca</surname><given-names>I</given-names></name><name><surname>Lome&#x000f1;a</surname><given-names>F</given-names></name><name><surname>Vilas</surname><given-names>D</given-names></name><name><surname>LLad&#x000f3;</surname><given-names>A</given-names></name><name><surname>Gaig</surname><given-names>C</given-names></name><name><surname>Santamaria</surname><given-names>J</given-names></name></person-group>
<year>2013</year>
<article-title>Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study</article-title>
<source>Lancet Neurol</source>
<volume>12</volume>
<fpage>443</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="pmid">23562390</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Godau</surname><given-names>J</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Behnke</surname><given-names>S</given-names></name><name><surname>Liepelt-Scarfone</surname><given-names>I</given-names></name><name><surname>Lerche</surname><given-names>S</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Gaenslen</surname><given-names>A</given-names></name><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Huber</surname><given-names>H</given-names></name><name><surname>Srulijes</surname><given-names>K</given-names></name><name><surname>Klenk</surname><given-names>J</given-names></name><name><surname>Fassbender</surname><given-names>K</given-names></name><name><surname>Maetzler</surname><given-names>W</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2013</year>
<article-title>The PRIPS study: Screening battery for subjects at risk for Parkinson&#x02019;s disease</article-title>
<source>Eur J Neurol</source>
<volume>20</volume>
<fpage>102</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="pmid">22852790</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Popper</surname><given-names>J</given-names></name><name><surname>Masaki</surname><given-names>K</given-names></name><name><surname>Launer</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>LR</given-names></name></person-group>
<year>2008</year>
<article-title>Association of olfactory dysfunction with risk for future Parkinson&#x02019;s disease</article-title>
<source>Ann Neurol</source>
<volume>63</volume>
<fpage>167</fpage>
<lpage>173</lpage>
<pub-id pub-id-type="pmid">18067173</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stern</surname><given-names>MB</given-names></name><name><surname>Lang</surname><given-names>A</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2012</year>
<article-title>Toward a redefinition of Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>54</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">22252891</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Bloem</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>Marek</surname><given-names>K</given-names></name><name><surname>Obeso</surname><given-names>J</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Deuschl</surname><given-names>G</given-names></name></person-group>
<year>2014</year>
<article-title>Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>29</volume>
<fpage>454</fpage>
<lpage>462</lpage>
<pub-id pub-id-type="pmid">24619848</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name></person-group>
<year>2009</year>
<article-title>Neuropathological assessment of Parkinson&#x02019;s disease: Refining the diagnostic criteria</article-title>
<source>Lancet Neurol</source>
<volume>8</volume>
<fpage>1150</fpage>
<lpage>1157</lpage>
<pub-id pub-id-type="pmid">19909913</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vingerhoets</surname><given-names>FJ</given-names></name><name><surname>Schulzer</surname><given-names>M</given-names></name><name><surname>Calne</surname><given-names>DB</given-names></name><name><surname>Snow</surname><given-names>BJ</given-names></name></person-group>
<year>1997</year>
<article-title>Which clinical sign of Parkinson&#x02019;s disease best reflects the nigrostriatal lesion?</article-title>
<source>Ann Neurol</source>
<volume>41</volume>
<fpage>58</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">9005866</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buchman</surname><given-names>AS</given-names></name><name><surname>Shulman</surname><given-names>JM</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Leurgans</surname><given-names>SE</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Morris</surname><given-names>MC</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name></person-group>
<year>2012</year>
<article-title>Nigral pathology and parkinsonian signs in elders without Parkinson disease</article-title>
<source>Ann Neurol</source>
<volume>71</volume>
<fpage>258</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="pmid">22367997</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Markesbery</surname><given-names>W</given-names></name><name><surname>Davis</surname><given-names>D</given-names></name><name><surname>Hardman</surname><given-names>J</given-names></name><name><surname>Launer</surname><given-names>L</given-names></name><name><surname>Masaki</surname><given-names>K</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>White</surname><given-names>LR</given-names></name></person-group>
<year>2004</year>
<article-title>Parkinsonian signs and substantia nigra neuron density in decendents elders without PD</article-title>
<source>Ann Neurol</source>
<volume>56</volume>
<fpage>532</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="pmid">15389895</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Fujishiro</surname><given-names>H</given-names></name><name><surname>DelleDonne</surname><given-names>A</given-names></name><name><surname>Menke</surname><given-names>J</given-names></name><name><surname>Ahmed</surname><given-names>Z</given-names></name><name><surname>Klos</surname><given-names>KJ</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Frigerio</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>M</given-names></name><name><surname>Parisi</surname><given-names>JR</given-names></name><name><surname>Ahlskog</surname><given-names>JE</given-names></name></person-group>
<year>2008</year>
<article-title>Evidence that incidental Lewy body disease is pre-symptomatic Parkinson&#x02019;s disease</article-title>
<source>ActaNeuropathol</source>
<volume>115</volume>
<fpage>437</fpage>
<lpage>444</lpage>
</element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Davis</surname><given-names>DG</given-names></name><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name><name><surname>Hardman</surname><given-names>J</given-names></name><name><surname>Masaki</surname><given-names>K</given-names></name><name><surname>Launer</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>LR</given-names></name></person-group>
<year>2006</year>
<article-title>Association of olfactory dysfunction with incidental Lewy bodies</article-title>
<source>Mov Disord</source>
<volume>21</volume>
<fpage>2062</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">16991138</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Davis</surname><given-names>DG</given-names></name><name><surname>Masaki</surname><given-names>KH</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><name><surname>White</surname><given-names>LR</given-names></name></person-group>
<year>2007</year>
<article-title>Bowel movement frequency in late-life and incidental Lewy bodies</article-title>
<source>Mov Disord</source>
<volume>22</volume>
<fpage>1581</fpage>
<lpage>1586</lpage>
<pub-id pub-id-type="pmid">17523195</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kraemmer</surname><given-names>J</given-names></name><name><surname>Kovacs</surname><given-names>GG</given-names></name><name><surname>Perju-Dumbrava</surname><given-names>L</given-names></name><name><surname>Pirker</surname><given-names>S</given-names></name><name><surname>Traub-Weidinger</surname><given-names>T</given-names></name><name><surname>Pirker</surname><given-names>W</given-names></name></person-group>
<year>2014</year>
<article-title>Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts</article-title>
<source>Mov Disord</source>
<volume>29</volume>
<fpage>1767</fpage>
<lpage>1773</lpage>
<pub-id pub-id-type="pmid">25048738</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marek</surname><given-names>K</given-names></name><name><surname>Innis</surname><given-names>R</given-names></name><name><surname>van Dyck</surname><given-names>C</given-names></name><name><surname>Fussell</surname><given-names>B</given-names></name><name><surname>Early</surname><given-names>M</given-names></name><name><surname>Eberly</surname><given-names>S</given-names></name><name><surname>Oakes</surname><given-names>D</given-names></name><name><surname>Seibyl</surname><given-names>J</given-names></name></person-group>
<year>2001</year>
<article-title>[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson&#x02019;s disease progression</article-title>
<source>Neurology</source>
<volume>57</volume>
<fpage>2089</fpage>
<lpage>2094</lpage>
<pub-id pub-id-type="pmid">11739831</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Godau</surname><given-names>J</given-names></name><name><surname>Hussl</surname><given-names>A</given-names></name><name><surname>Lolekha</surname><given-names>P</given-names></name><name><surname>Stoessl</surname><given-names>AJ</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name></person-group>
<year>2012</year>
<article-title>Neuroimaging: Current role in detecting pre-motor Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>634</fpage>
<lpage>643</lpage>
<pub-id pub-id-type="pmid">22508281</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morrish</surname><given-names>PK</given-names></name><name><surname>Rakshi</surname><given-names>JS</given-names></name><name><surname>Bailey</surname><given-names>DL</given-names></name><name><surname>Sawle</surname><given-names>GV</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name></person-group>
<year>1998</year>
<article-title>Measuring the rate of progression and estimating the preclinical period of Parkinson&#x02019;s disease with [18F]dopa PET</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<volume>64</volume>
<fpage>314</fpage>
<lpage>319</lpage>
<pub-id pub-id-type="pmid">9527140</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De La Fuente-Fern&#x000e1;ndez</surname><given-names>R</given-names></name><name><surname>Schulzer</surname><given-names>M</given-names></name><name><surname>Kuramoto</surname><given-names>L</given-names></name><name><surname>Cragg</surname><given-names>J</given-names></name><name><surname>Ramachandiran</surname><given-names>N</given-names></name><name><surname>Au</surname><given-names>WL</given-names></name><name><surname>Mak</surname><given-names>E</given-names></name><name><surname>McKenzie</surname><given-names>J</given-names></name><name><surname>McCormick</surname><given-names>S</given-names></name><name><surname>Sossi</surname><given-names>V</given-names></name><name><surname>Ruth</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>CS</given-names></name><name><surname>Calne</surname><given-names>DB</given-names></name><name><surname>Stoessl</surname><given-names>AJ</given-names></name></person-group>
<year>2011</year>
<article-title>Age-specific progression of nigrostriatal dysfunction in Parkinson&#x02019;s disease</article-title>
<source>Ann Neurol</source>
<volume>69</volume>
<fpage>803</fpage>
<lpage>810</lpage>
<pub-id pub-id-type="pmid">21246604</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hilker</surname><given-names>R</given-names></name><name><surname>Schweitzer</surname><given-names>K</given-names></name><name><surname>Coburger</surname><given-names>S</given-names></name><name><surname>Ghaemi</surname><given-names>M</given-names></name><name><surname>Weisenbach</surname><given-names>S</given-names></name><name><surname>Jacobs</surname><given-names>AH</given-names></name><name><surname>Rudolf</surname><given-names>J</given-names></name><name><surname>Herholz</surname><given-names>K</given-names></name><name><surname>Heiss</surname><given-names>W-D</given-names></name></person-group>
<year>2005</year>
<article-title>Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity</article-title>
<source>Arch Neurol</source>
<volume>62</volume>
<fpage>378</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="pmid">15767502</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bezard</surname><given-names>E</given-names></name><name><surname>Gross</surname><given-names>CE</given-names></name><name><surname>Brotchie</surname><given-names>JM</given-names></name></person-group>
<year>2003</year>
<article-title>Presymptomatic compensation in Parkinson&#x02019;s disease is not dopamine-mediated</article-title>
<source>Trends Neurosci</source>
<volume>26</volume>
<fpage>215</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="pmid">12689773</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Nuenen</surname><given-names>BFL</given-names></name><name><surname>Van Eimeren</surname><given-names>T</given-names></name><name><surname>Van Der Vegt</surname><given-names>JPM</given-names></name><name><surname>Buhmann</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Siebner</surname><given-names>HR</given-names></name></person-group>
<year>2009</year>
<article-title>Mapping preclinical compensation in Parkinson&#x02019;s disease: An imaging genomics approach</article-title>
<source>Mov Disord</source>
<volume>24</volume>
<issue>Suppl 2</issue>
<fpage>S703</fpage>
<lpage>S710</lpage>
<pub-id pub-id-type="pmid">19877238</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maetzler</surname><given-names>W</given-names></name><name><surname>Hausdorff</surname><given-names>JM</given-names></name></person-group>
<year>2012</year>
<article-title>Motor signs in the prodromal phase of Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>627</fpage>
<lpage>633</lpage>
<pub-id pub-id-type="pmid">22437964</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><name><surname>Murray</surname><given-names>AM</given-names></name><name><surname>Shannon</surname><given-names>KM</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Pilgrim</surname><given-names>DM</given-names></name><name><surname>Evans</surname><given-names>DA</given-names></name></person-group>
<year>1996</year>
<article-title>Prevalence of parkinsonian signs and associated mortality in a community population of older people</article-title>
<source>N Engl J Med</source>
<volume>334</volume>
<fpage>71</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">8531961</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Louis</surname><given-names>ED</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name></person-group>
<year>2007</year>
<article-title>Mild Parkinsonian signs: An overview of an emerging concept</article-title>
<source>Mov Disord</source>
<volume>22</volume>
<fpage>1681</fpage>
<lpage>1688</lpage>
<pub-id pub-id-type="pmid">17534951</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Gagnon</surname><given-names>JF</given-names></name><name><surname>Pelletier</surname><given-names>A</given-names></name><name><surname>Montplaisir</surname><given-names>JY</given-names></name></person-group>
<year>2012</year>
<article-title>How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder</article-title>
<source>Brain</source>
<volume>135</volume>
<fpage>1860</fpage>
<lpage>1870</lpage>
<pub-id pub-id-type="pmid">22561644</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mirelman</surname><given-names>A</given-names></name><name><surname>Gurevich</surname><given-names>T</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name><name><surname>Bar-Shira</surname><given-names>A</given-names></name><name><surname>Orr-Urtreger</surname><given-names>A</given-names></name><name><surname>Hausdorff</surname><given-names>JM</given-names></name></person-group>
<year>2011</year>
<article-title>Gait alterations in healthy carriers of the LRRK2 G2019S mutation</article-title>
<source>Ann Neurol</source>
<volume>69</volume>
<fpage>193</fpage>
<lpage>197</lpage>
<pub-id pub-id-type="pmid">21280089</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maetzler</surname><given-names>W</given-names></name><name><surname>Mancini</surname><given-names>M</given-names></name><name><surname>Liepelt-Scarfone</surname><given-names>I</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>K</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>van Lummel</surname><given-names>RC</given-names></name><name><surname>Ainsworth</surname><given-names>E</given-names></name><name><surname>Hobert</surname><given-names>M</given-names></name><name><surname>Streffer</surname><given-names>J</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Chiari</surname><given-names>L</given-names></name></person-group>
<year>2012</year>
<article-title>Impaired trunk stability in individuals at high risk for Parkinson&#x02019;s disease</article-title>
<source>PLoS One</source>
<volume>7</volume>
<fpage>e32240</fpage>
<pub-id pub-id-type="pmid">22457713</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noyce</surname><given-names>AJ</given-names></name><name><surname>Bestwick</surname><given-names>JP</given-names></name><name><surname>Silveira-Moriyama</surname><given-names>L</given-names></name><name><surname>Hawkes</surname><given-names>CH</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Schrag</surname><given-names>A</given-names></name></person-group>
<year>2012</year>
<article-title>Meta-analysis of early nonmotor features and risk factors for Parkinson disease</article-title>
<source>Ann Neurol</source>
<volume>72</volume>
<fpage>893</fpage>
<lpage>901</lpage>
<pub-id pub-id-type="pmid">23071076</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noyce</surname><given-names>AJ</given-names></name><name><surname>Bestwick</surname><given-names>JP</given-names></name><name><surname>Silveira-Moriyama</surname><given-names>L</given-names></name><name><surname>Hawkes</surname><given-names>CH</given-names></name><name><surname>Knowles</surname><given-names>CH</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Giovannoni</surname><given-names>G</given-names></name><name><surname>Nageshwaran</surname><given-names>S</given-names></name><name><surname>Osborne</surname><given-names>C</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Schrag</surname><given-names>A</given-names></name></person-group>
<year>2014</year>
<article-title>PREDICT-PD: Identifying risk of Parkinson&#x02019;s disease in the community: Methods and baseline results</article-title>
<source>J Neurol NeurosurgPsychiatry</source>
<volume>85</volume>
<fpage>31</fpage>
<lpage>37</lpage>
</element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Antonini</surname><given-names>A</given-names></name><name><surname>Colosimo</surname><given-names>C</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><name><surname>Morgante</surname><given-names>L</given-names></name><name><surname>Avarello</surname><given-names>TP</given-names></name><name><surname>Bottacchi</surname><given-names>E</given-names></name><name><surname>Cannas</surname><given-names>A</given-names></name><name><surname>Ceravolo</surname><given-names>G</given-names></name><name><surname>Ceravolo</surname><given-names>R</given-names></name><name><surname>Cicarelli</surname><given-names>G</given-names></name><name><surname>Gaglio</surname><given-names>RM</given-names></name><name><surname>Giglia</surname><given-names>RM</given-names></name><name><surname>Iemolo</surname><given-names>F</given-names></name><name><surname>Manfredi</surname><given-names>M</given-names></name><name><surname>Meco</surname><given-names>G</given-names></name><name><surname>Nicoletti</surname><given-names>A</given-names></name><name><surname>Pederzoli</surname><given-names>M</given-names></name><name><surname>Petrone</surname><given-names>A</given-names></name><name><surname>Pisani</surname><given-names>A</given-names></name><name><surname>Pontieri</surname><given-names>FE</given-names></name><name><surname>Quatrale</surname><given-names>R</given-names></name><name><surname>Ramat</surname><given-names>S</given-names></name><name><surname>Scala</surname><given-names>R</given-names></name><name><surname>Volpe</surname><given-names>G</given-names></name><name><surname>Zappulla</surname><given-names>S</given-names></name><name><surname>Bentivoglio</surname><given-names>AR</given-names></name><name><surname>Stocchi</surname><given-names>F</given-names></name><name><surname>Trianni</surname><given-names>G</given-names></name><name><surname>Del Dotto</surname><given-names>P</given-names></name></person-group>
<year>2009</year>
<article-title>The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>24</volume>
<fpage>1641</fpage>
<lpage>1649</lpage>
<pub-id pub-id-type="pmid">19514014</pub-id></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erro</surname><given-names>R</given-names></name><name><surname>Picillo</surname><given-names>M</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Amboni</surname><given-names>M</given-names></name><name><surname>Moccia</surname><given-names>M</given-names></name><name><surname>Longo</surname><given-names>K</given-names></name><name><surname>Cozzolino</surname><given-names>A</given-names></name><name><surname>Giordano</surname><given-names>F</given-names></name><name><surname>Rosa</surname><given-names>A De</given-names></name><name><surname>Michele</surname><given-names>G De</given-names></name><name><surname>Pellecchia</surname><given-names>MT</given-names></name><name><surname>Barone</surname><given-names>P</given-names></name></person-group>
<year>2013</year>
<article-title>Non-motor symptoms in early Parkinson&#x02019;s disease: A 2-year follow-up study on previously untreated patients</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<volume>84</volume>
<fpage>14</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">22993448</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khoo</surname><given-names>TK</given-names></name><name><surname>Yarnall</surname><given-names>AJ</given-names></name><name><surname>Duncan</surname><given-names>GW</given-names></name><name><surname>Coleman</surname><given-names>S</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>JT</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name></person-group>
<year>2013</year>
<article-title>The spectrum of nonmotor symptoms in early Parkinson disease</article-title>
<source>Neurology</source>
<volume>80</volume>
<fpage>276</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="pmid">23319473</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2008</year>
<article-title>Non-motor symptoms in Parkinson&#x02019;s disease</article-title>
<source>Eur J Neurol</source>
<volume>15</volume>
<fpage>14</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">18353132</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Hawkes</surname><given-names>CH</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><name><surname>Ziemssen</surname><given-names>T</given-names></name></person-group>
<year>2012</year>
<article-title>Identifying prodromal Parkinson&#x02019;s disease: Pre-Motor disorders in Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>617</fpage>
<lpage>626</lpage>
<pub-id pub-id-type="pmid">22508280</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name><name><surname>R&#x000fc;b</surname><given-names>U</given-names></name><name><surname>RaI</surname><given-names>De Vos</given-names></name><name><surname>ENH</surname><given-names>Jansen Steur</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group>
<year>2003</year>
<article-title>Staging of brain pathology related to sporadic Parkinson&#x02019;s disease</article-title>
<source>Neurobiol Aging</source>
<volume>24</volume>
<fpage>197</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="pmid">12498954</pub-id></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ponsen</surname><given-names>MM</given-names></name><name><surname>Stoffers</surname><given-names>D</given-names></name><name><surname>Wolters</surname><given-names>EC</given-names></name><name><surname>Booij</surname><given-names>J</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name></person-group>
<year>2010</year>
<article-title>Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson&#x02019;s disease</article-title>
<source>J Neurol Neurosurg Psychiatry</source>
<volume>81</volume>
<fpage>396</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="pmid">19965851</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Gagnon</surname><given-names>J-F</given-names></name><name><surname>Vendette</surname><given-names>M</given-names></name><name><surname>Desjardins</surname><given-names>C</given-names></name><name><surname>Montplaisir</surname><given-names>JY</given-names></name></person-group>
<year>2011</year>
<article-title>Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder</article-title>
<source>Ann Neurol</source>
<volume>69</volume>
<fpage>811</fpage>
<lpage>818</lpage>
<pub-id pub-id-type="pmid">21246603</pub-id></element-citation></ref><ref id="r51"><label>51</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ritz</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Lassen</surname><given-names>CF</given-names></name><name><surname>Arah</surname><given-names>OA</given-names></name></person-group>
<year>2014</year>
<article-title>Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease</article-title>
<source>Neurology</source>
<volume>83</volume>
<fpage>1396</fpage>
<lpage>1402</lpage>
<pub-id pub-id-type="pmid">25217056</pub-id></element-citation></ref><ref id="r52"><label>52</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moccia</surname><given-names>M</given-names></name><name><surname>Erro</surname><given-names>R</given-names></name><name><surname>Picillo</surname><given-names>M</given-names></name><name><surname>Vassallo</surname><given-names>E</given-names></name><name><surname>Vitale</surname><given-names>C</given-names></name><name><surname>Longo</surname><given-names>K</given-names></name><name><surname>Amboni</surname><given-names>M</given-names></name><name><surname>Santangelo</surname><given-names>G</given-names></name><name><surname>Palladino</surname><given-names>R</given-names></name><name><surname>Nardone</surname><given-names>A</given-names></name><name><surname>Triassi</surname><given-names>M</given-names></name><name><surname>Barone</surname><given-names>P</given-names></name><name><surname>Pellecchia</surname><given-names>MT</given-names></name></person-group>
<year>2015</year>
<article-title>Quitting smoking: An early non-motor feature of Parkinson&#x02019;s disease?</article-title>
<source>Parkinsonism Relat Disord</source>
<volume>21</volume>
<fpage>216</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="pmid">25547948</pub-id></element-citation></ref><ref id="r53"><label>53</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>AJ</given-names></name><name><surname>Sarwar</surname><given-names>AI</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Viswanathan</surname><given-names>A</given-names></name></person-group>
<year>2014</year>
<article-title>Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism</article-title>
<source>World Neurosurg</source>
<volume>82</volume>
<fpage>241.e1</fpage>
<lpage>241.e4</lpage>
<pub-id pub-id-type="pmid">24076056</pub-id></element-citation></ref><ref id="r54"><label>54</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schenck</surname><given-names>CH</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><name><surname>Mahowald</surname><given-names>MW</given-names></name></person-group>
<year>2013</year>
<article-title>Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: A 16-year update on a previously reported series</article-title>
<source>Sleep Med</source>
<volume>14</volume>
<fpage>744</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="pmid">23347909</pub-id></element-citation></ref><ref id="r55"><label>55</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Masaki</surname><given-names>KH</given-names></name><name><surname>Nelson</surname><given-names>JS</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name></person-group>
<year>2005</year>
<article-title>Excessive daytime sleepiness and subsequent development of Parkinson disease</article-title>
<source>Neurology</source>
<volume>65</volume>
<fpage>1442</fpage>
<lpage>1446</lpage>
<pub-id pub-id-type="pmid">16275833</pub-id></element-citation></ref><ref id="r56"><label>56</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doty</surname><given-names>RL</given-names></name></person-group>
<year>2012</year>
<article-title>Olfactory dysfunction in Parkinson disease</article-title>
<source>Nat Rev Neurol</source>
<volume>8</volume>
<fpage>329</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="pmid">22584158</pub-id></element-citation></ref><ref id="r57"><label>57</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haehner</surname><given-names>A</given-names></name><name><surname>Boesveldt</surname><given-names>S</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name><name><surname>Mackay-Sim</surname><given-names>A</given-names></name><name><surname>Fleischmann</surname><given-names>J</given-names></name><name><surname>Silburn</surname><given-names>PA</given-names></name><name><surname>Johnston</surname><given-names>AN</given-names></name><name><surname>Mellick</surname><given-names>GD</given-names></name><name><surname>Herting</surname><given-names>B</given-names></name><name><surname>Reichmann</surname><given-names>H</given-names></name><name><surname>Hummel</surname><given-names>T</given-names></name></person-group>
<year>2009</year>
<article-title>Prevalence of smell loss in Parkinson&#x02019;s disease - A multicenter study</article-title>
<source>Parkinsonism Relat Disord</source>
<volume>15</volume>
<fpage>490</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="pmid">19138875</pub-id></element-citation></ref><ref id="r58"><label>58</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>H&#x000f6;gl</surname><given-names>B</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>C</given-names></name><name><surname>Santamar&#x000ed;a</surname><given-names>J</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Serradell</surname><given-names>M</given-names></name><name><surname>Mitterling</surname><given-names>T</given-names></name><name><surname>Gschliesser</surname><given-names>V</given-names></name><name><surname>Goebel</surname><given-names>G</given-names></name><name><surname>Brugger</surname><given-names>F</given-names></name><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><collab>Sleep Innsbruck Barcelona Group</collab></person-group>
<year>2015</year>
<article-title>Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD</article-title>
<source>Neurology</source>
<volume>84</volume>
<fpage>654</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="pmid">25609758</pub-id></element-citation></ref><ref id="r59"><label>59</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schenck</surname><given-names>CH</given-names></name><name><surname>Bundlie</surname><given-names>SR</given-names></name><name><surname>Ettinger</surname><given-names>MG</given-names></name><name><surname>Mahowald</surname><given-names>MW</given-names></name></person-group>
<year>1986</year>
<article-title>Chronic behavioral disorders of human REM sleep: A new category of parasomnia</article-title>
<source>Sleep</source>
<volume>9</volume>
<fpage>293</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="pmid">3505730</pub-id></element-citation></ref><ref id="r60"><label>60</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gagnon</surname><given-names>JF</given-names></name><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Mazza</surname><given-names>S</given-names></name><name><surname>Doyon</surname><given-names>J</given-names></name><name><surname>Montplaisir</surname><given-names>J</given-names></name></person-group>
<year>2006</year>
<article-title>Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases</article-title>
<source>Lancet Neurol</source>
<volume>5</volume>
<fpage>424</fpage>
<lpage>432</lpage>
<pub-id pub-id-type="pmid">16632313</pub-id></element-citation></ref><ref id="r61"><label>61</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Djamshidian</surname><given-names>A</given-names></name><name><surname>Nocker</surname><given-names>M</given-names></name><name><surname>Rastner</surname><given-names>V</given-names></name><name><surname>Defrancesco</surname><given-names>M</given-names></name><name><surname>Rungger</surname><given-names>G</given-names></name><name><surname>Gasperi</surname><given-names>A</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>H&#x000f6;gl</surname><given-names>B</given-names></name></person-group>
<year>2015</year>
<article-title>Probable RBD and association with neurodegenerative disease markers: A population-based study</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>1417</fpage>
<lpage>1421</lpage>
<pub-id pub-id-type="pmid">26208108</pub-id></element-citation></ref><ref id="r62"><label>62</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Gagnon</surname><given-names>JF</given-names></name><name><surname>Vendette</surname><given-names>M</given-names></name><name><surname>Fantini</surname><given-names>ML</given-names></name><name><surname>Massicotte-Marquez</surname><given-names>J</given-names></name><name><surname>Montplaisir</surname><given-names>J</given-names></name></person-group>
<year>2009</year>
<article-title>Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder</article-title>
<source>Neurology</source>
<volume>72</volume>
<fpage>1296</fpage>
<lpage>1300</lpage>
<pub-id pub-id-type="pmid">19109537</pub-id></element-citation></ref><ref id="r63"><label>63</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Hogl</surname><given-names>B</given-names></name><name><surname>Arnulf</surname><given-names>I</given-names></name><name><surname>Ferini-Strambi</surname><given-names>L</given-names></name><name><surname>Manni</surname><given-names>R</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><name><surname>Ju</surname><given-names>Y-E</given-names></name><name><surname>Puligheddu</surname><given-names>M</given-names></name><name><surname>Sonka</surname><given-names>K</given-names></name><name><surname>Pelletier</surname><given-names>A</given-names></name><name><surname>Santamaria</surname><given-names>J</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>Leu-Semenescu</surname><given-names>S</given-names></name><name><surname>Zucconi</surname><given-names>M</given-names></name><name><surname>Terzaghi</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Unger</surname><given-names>MM</given-names></name><name><surname>Carlander</surname><given-names>B</given-names></name><name><surname>Fantini</surname><given-names>M-L</given-names></name><name><surname>Montplaisir</surname><given-names>JY</given-names></name></person-group>
<year>2015</year>
<article-title>Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study</article-title>
<source>Ann Neurol</source>
<volume>77</volume>
<fpage>830</fpage>
<lpage>839</lpage>
<pub-id pub-id-type="pmid">25767079</pub-id></element-citation></ref><ref id="r64"><label>64</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Davis</surname><given-names>DG</given-names></name><name><surname>Masaki</surname><given-names>KH</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Curb</surname><given-names>JD</given-names></name><name><surname>White</surname><given-names>LR</given-names></name></person-group>
<year>2007</year>
<article-title>Bowel movement frequency in late-life and incidental Lewy bodies</article-title>
<source>Mov Disord</source>
<volume>22</volume>
<fpage>1581</fpage>
<lpage>1586</lpage>
<pub-id pub-id-type="pmid">17523195</pub-id></element-citation></ref><ref id="r65"><label>65</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pouclet</surname><given-names>H</given-names></name><name><surname>Lebouvier</surname><given-names>T</given-names></name><name><surname>Coron</surname><given-names>E</given-names></name><name><surname>Bruley des Varannes</surname><given-names>S</given-names></name><name><surname>Rouaud</surname><given-names>T</given-names></name><name><surname>Roy</surname><given-names>M</given-names></name><name><surname>Neunlist</surname><given-names>M</given-names></name><name><surname>Derkinderen</surname><given-names>P</given-names></name></person-group>
<year>2012</year>
<article-title>A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson&#x02019;s disease</article-title>
<source>Neurobiol Dis</source>
<volume>45</volume>
<fpage>305</fpage>
<lpage>309</lpage>
<pub-id pub-id-type="pmid">21878391</pub-id></element-citation></ref><ref id="r66"><label>66</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shannon</surname><given-names>KM</given-names></name><name><surname>Keshavarzian</surname><given-names>A</given-names></name><name><surname>Mutlu</surname><given-names>E</given-names></name><name><surname>Dodiya</surname><given-names>HB</given-names></name><name><surname>Daian</surname><given-names>D</given-names></name><name><surname>Jaglin</surname><given-names>JA</given-names></name><name><surname>Kordower</surname><given-names>JH</given-names></name></person-group>
<year>2012</year>
<article-title>Alpha-synuclein in colonic submucosa in early untreated Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>709</fpage>
<lpage>715</lpage>
<pub-id pub-id-type="pmid">21766334</pub-id></element-citation></ref><ref id="r67"><label>67</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siderowf</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name></person-group>
<year>2012</year>
<article-title>Premotor Parkinson&#x02019;sdisease: Concepts and definitions</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>608</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="pmid">22508279</pub-id></element-citation></ref><ref id="r68"><label>68</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Definitions</surname><given-names>B</given-names></name><name><surname>Group</surname><given-names>W</given-names></name></person-group>
<year>2001</year>
<article-title>Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework</article-title>
<source>Clin Pharmacol Ther</source>
<volume>69</volume>
<fpage>89</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="pmid">11240971</pub-id></element-citation></ref><ref id="r69"><label>69</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ponsen</surname><given-names>MM</given-names></name><name><surname>Stoffers</surname><given-names>D</given-names></name><name><surname>Booij</surname><given-names>J</given-names></name><name><surname>Van Eck-Smit</surname><given-names>BLF</given-names></name><name><surname>Wolters</surname><given-names>EC</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name></person-group>
<year>2004</year>
<article-title>Idiopathic hyposmia as a preclinical sign of Parkinson&#x02019;s disease</article-title>
<source>Ann Neurol</source>
<volume>56</volume>
<fpage>173</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="pmid">15293269</pub-id></element-citation></ref><ref id="r70"><label>70</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Valldeoriola</surname><given-names>F</given-names></name><name><surname>Lome&#x000f1;a</surname><given-names>F</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Serradell</surname><given-names>M</given-names></name><name><surname>Salamero</surname><given-names>M</given-names></name><name><surname>Cot</surname><given-names>A</given-names></name><name><surname>Ros</surname><given-names>D</given-names></name><name><surname>Pav&#x000ed;a</surname><given-names>J</given-names></name><name><surname>Santamaria</surname><given-names>J</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name></person-group>
<year>2011</year>
<article-title>Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study</article-title>
<source>Lancet Neurol</source>
<volume>10</volume>
<fpage>797</fpage>
<lpage>805</lpage>
<pub-id pub-id-type="pmid">21802993</pub-id></element-citation></ref><ref id="r71"><label>71</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jennings</surname><given-names>D</given-names></name><name><surname>Siderowf</surname><given-names>A</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Seibyl</surname><given-names>J</given-names></name><name><surname>Eberly</surname><given-names>S</given-names></name><name><surname>Oakes</surname><given-names>D</given-names></name><name><surname>Marek</surname><given-names>K</given-names></name><collab>PARS Investigators</collab></person-group>
<year>2014</year>
<article-title>Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study</article-title>
<source>Neurology</source>
<volume>83</volume>
<fpage>1739</fpage>
<lpage>1746</lpage>
<pub-id pub-id-type="pmid">25298306</pub-id></element-citation></ref><ref id="r72"><label>72</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eberling</surname><given-names>JL</given-names></name><name><surname>Dave</surname><given-names>KD</given-names></name><name><surname>Frasier</surname><given-names>MA</given-names></name></person-group>
<year>2013</year>
<article-title>&#x003b1;-synuclein imaging: A critical need for Parkinson&#x02019;s disease research</article-title>
<source>J Parkinsons Dis</source>
<volume>3</volume>
<fpage>565</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="pmid">24192754</pub-id></element-citation></ref><ref id="r73"><label>73</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>Schocke</surname><given-names>M</given-names></name><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Gschliesser</surname><given-names>V</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Santamaria</surname><given-names>J</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>H&#x000f6;gl</surname><given-names>B</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2011</year>
<article-title>White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion-tensor imaging and voxel-based morphometry study</article-title>
<source>Ann Neurol</source>
<volume>69</volume>
<fpage>400</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">21387382</pub-id></element-citation></ref><ref id="r74"><label>74</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Unger</surname><given-names>MM</given-names></name><name><surname>Belke</surname><given-names>M</given-names></name><name><surname>Menzler</surname><given-names>K</given-names></name><name><surname>Heverhagen</surname><given-names>JT</given-names></name><name><surname>Keil</surname><given-names>B</given-names></name><name><surname>Stiasny-Kolster</surname><given-names>K</given-names></name><name><surname>Rosenow</surname><given-names>F</given-names></name><name><surname>Diederich</surname><given-names>NJ</given-names></name><name><surname>Mayer</surname><given-names>G</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>JC</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Knake</surname><given-names>S</given-names></name></person-group>
<year>2010</year>
<article-title>Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions</article-title>
<source>Sleep</source>
<volume>33</volume>
<fpage>767</fpage>
<lpage>773</lpage>
<pub-id pub-id-type="pmid">20550017</pub-id></element-citation></ref><ref id="r75"><label>75</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rolheiser</surname><given-names>TM</given-names></name><name><surname>Fulton</surname><given-names>HG</given-names></name><name><surname>Good</surname><given-names>KP</given-names></name><name><surname>Fisk</surname><given-names>JD</given-names></name><name><surname>McKelvey</surname><given-names>JR</given-names></name><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Khan</surname><given-names>NM</given-names></name><name><surname>Leslie</surname><given-names>RA</given-names></name><name><surname>Robertson</surname><given-names>HA</given-names></name></person-group>
<year>2011</year>
<article-title>Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson&#x02019;s disease</article-title>
<source>J Neurol</source>
<volume>258</volume>
<fpage>1254</fpage>
<lpage>1260</lpage>
<pub-id pub-id-type="pmid">21287185</pub-id></element-citation></ref><ref id="r76"><label>76</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vaillancourt</surname><given-names>DE</given-names></name><name><surname>Prodoehl</surname><given-names>J</given-names></name><name><surname>Abraham</surname><given-names>I</given-names></name><name><surname>Corcos</surname><given-names>DM</given-names></name><name><surname>Zhou</surname><given-names>XJ</given-names></name><name><surname>Cornelia</surname><given-names>CL</given-names></name><name><surname>Little</surname><given-names>DM</given-names></name></person-group>
<year>2009</year>
<article-title>High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease</article-title>
<source>Neurology</source>
<volume>72</volume>
<fpage>1378</fpage>
<lpage>1384</lpage>
<pub-id pub-id-type="pmid">19129507</pub-id></element-citation></ref><ref id="r77"><label>77</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Schocke</surname><given-names>MF</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Esterhammer</surname><given-names>R</given-names></name><name><surname>Brenneis</surname><given-names>C</given-names></name><name><surname>Jaschke</surname><given-names>W</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2006</year>
<article-title>Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson&#x02019;s disease</article-title>
<source>Brain</source>
<volume>129</volume>
<fpage>538</fpage>
<lpage>542</lpage>
<pub-id pub-id-type="pmid">16272163</pub-id></element-citation></ref><ref id="r78"><label>78</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ibarretxe-Bilbao</surname><given-names>N</given-names></name><name><surname>Junque</surname><given-names>C</given-names></name><name><surname>Marti</surname><given-names>MJ</given-names></name><name><surname>Valldeoriola</surname><given-names>F</given-names></name><name><surname>Vendrell</surname><given-names>P</given-names></name><name><surname>Bargallo</surname><given-names>N</given-names></name><name><surname>Zarei</surname><given-names>M</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name></person-group>
<year>2010</year>
<article-title>Olfactory impairment in Parkinson&#x02019;s disease and white matter abnormalities in central olfactory areas: A voxel-based diffusion tensor imaging study</article-title>
<source>Mov Disord</source>
<volume>25</volume>
<fpage>1888</fpage>
<lpage>1894</lpage>
<pub-id pub-id-type="pmid">20669268</pub-id></element-citation></ref><ref id="r79"><label>79</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blazejewska</surname><given-names>AI</given-names></name><name><surname>Schwarz</surname><given-names>ST</given-names></name><name><surname>Pitiot</surname><given-names>A</given-names></name><name><surname>Stephenson</surname><given-names>MC</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Bajaj</surname><given-names>N</given-names></name><name><surname>Bowtell</surname><given-names>RW</given-names></name><name><surname>Auer</surname><given-names>DP</given-names></name><name><surname>Gowland</surname><given-names>PA</given-names></name></person-group>
<year>2013</year>
<article-title>Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and <italic>in vivo</italic> 7 T MRI</article-title>
<source>Neurology</source>
<volume>81</volume>
<fpage>534</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="pmid">23843466</pub-id></element-citation></ref><ref id="r80"><label>80</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>ST</given-names></name><name><surname>Afzal</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>PS</given-names></name><name><surname>Bajaj</surname><given-names>N</given-names></name><name><surname>Gowland</surname><given-names>PA</given-names></name><name><surname>Auer</surname><given-names>DP</given-names></name></person-group>
<year>2014</year>
<article-title>The &#x0201c;swallow tail&#x0201d; appearance of the healthy nigrosome - a new accurate test of Parkinson&#x02019;sdisease: A case-control and retrospective cross-sectional MRI study at 3T</article-title>
<source>PLoS One</source>
<volume>9</volume>
<fpage>e93814</fpage>
<pub-id pub-id-type="pmid">24710392</pub-id></element-citation></ref><ref id="r81"><label>81</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reiter</surname><given-names>E</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name><name><surname>Pinter</surname><given-names>B</given-names></name><name><surname>Krismer</surname><given-names>F</given-names></name><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Esterhammer</surname><given-names>R</given-names></name><name><surname>Kremser</surname><given-names>C</given-names></name><name><surname>Schocke</surname><given-names>M</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name></person-group>
<year>2015</year>
<article-title>Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>1068</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="pmid">25773707</pub-id></element-citation></ref><ref id="r82"><label>82</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Gaenslen</surname><given-names>A</given-names></name></person-group>
<year>2010</year>
<article-title>Place value of transcranial sonography in early diagnosis of Parkinson&#x02019;s disease</article-title>
<source>Neurodegener Dis</source>
<volume>7</volume>
<fpage>291</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="pmid">20616564</pub-id></element-citation></ref><ref id="r83"><label>83</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Nocker</surname><given-names>M</given-names></name><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Schmidauer</surname><given-names>C</given-names></name><name><surname>Gasperi</surname><given-names>A</given-names></name><name><surname>Rungger</surname><given-names>G</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2013</year>
<article-title>Substantia nigra hyperechogenicity as a marker for parkinson&#x02019;s disease: A population-based study</article-title>
<source>Neurodegener Dis</source>
<volume>12</volume>
<fpage>212</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="pmid">23689066</pub-id></element-citation></ref><ref id="r84"><label>84</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behnke</surname><given-names>S</given-names></name><name><surname>Runkel</surname><given-names>A</given-names></name><name><surname>Kassar</surname><given-names>HAS</given-names></name><name><surname>Ortmann</surname><given-names>M</given-names></name><name><surname>Guidez</surname><given-names>D</given-names></name><name><surname>Dillmann</surname><given-names>U</given-names></name><name><surname>Fassbender</surname><given-names>K</given-names></name><name><surname>Spiegel</surname><given-names>J</given-names></name></person-group>
<year>2013</year>
<article-title>Long-term course of substantia nigra hyperechogenicity in Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>28</volume>
<fpage>455</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">23115064</pub-id></element-citation></ref><ref id="r85"><label>85</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Nocker</surname><given-names>M</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Scherfler</surname><given-names>C</given-names></name><name><surname>Sojer</surname><given-names>M</given-names></name><name><surname>Gasperi</surname><given-names>A</given-names></name><name><surname>Rungger</surname><given-names>G</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name></person-group>
<year>2012</year>
<article-title>A follow-up study of substantia nigra echogenicity in healthy adults</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>1196</fpage>
<lpage>1197</lpage>
<pub-id pub-id-type="pmid">22700445</pub-id></element-citation></ref><ref id="r86"><label>86</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Serradell</surname><given-names>M</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Valldeoriola</surname><given-names>F</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Vilaseca</surname><given-names>I</given-names></name><name><surname>Mitterling</surname><given-names>T</given-names></name><name><surname>Gaig</surname><given-names>C</given-names></name><name><surname>Vilas</surname><given-names>D</given-names></name><name><surname>Santamaria</surname><given-names>J</given-names></name><name><surname>H&#x000f6;gl</surname><given-names>B</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2014</year>
<article-title>Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder</article-title>
<source>Mov Disord</source>
<volume>29</volume>
<fpage>1774</fpage>
<lpage>1780</lpage>
<pub-id pub-id-type="pmid">25384461</pub-id></element-citation></ref><ref id="r87"><label>87</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Schr&#x000f6;der</surname><given-names>U</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Tatschner</surname><given-names>T</given-names></name><name><surname>Benz</surname><given-names>P</given-names></name><name><surname>Tucha</surname><given-names>O</given-names></name><name><surname>Preier</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>KW</given-names></name><name><surname>Reiners</surname><given-names>K</given-names></name><name><surname>Gerlach</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>G</given-names></name></person-group>
<year>2002</year>
<article-title>Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury</article-title>
<source>Arch Neurol</source>
<volume>59</volume>
<fpage>999</fpage>
<lpage>1005</lpage>
<pub-id pub-id-type="pmid">12056937</pub-id></element-citation></ref><ref id="r88"><label>88</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Godau</surname><given-names>J</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name><name><surname>Gerlach</surname><given-names>M</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name></person-group>
<year>2010</year>
<article-title>Microglia activation is related to substantia nigra echogenicity</article-title>
<source>J Neural Transm</source>
<volume>117</volume>
<fpage>1287</fpage>
<lpage>1292</lpage>
<pub-id pub-id-type="pmid">21057966</pub-id></element-citation></ref><ref id="r89"><label>89</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>G</given-names></name><name><surname>Zeiler</surname><given-names>B</given-names></name><name><surname>Tucha</surname><given-names>O</given-names></name><name><surname>Hofmann</surname><given-names>E</given-names></name><name><surname>Preier</surname><given-names>M</given-names></name><name><surname>Benz</surname><given-names>P</given-names></name><name><surname>Jost</surname><given-names>W</given-names></name><name><surname>Reiners</surname><given-names>K</given-names></name><name><surname>Lange</surname><given-names>KW</given-names></name></person-group>
<year>1999</year>
<article-title>Vulnerability of the nigrostriatal system as detected by transcranial ultrasound</article-title>
<source>Neurology</source>
<volume>53</volume>
<fpage>1026</fpage>
<lpage>1031</lpage>
<pub-id pub-id-type="pmid">10496262</pub-id></element-citation></ref><ref id="r90"><label>90</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Behnke</surname><given-names>S</given-names></name><name><surname>Schroeder</surname><given-names>U</given-names></name><name><surname>Dillmann</surname><given-names>U</given-names></name><name><surname>Buchholz</surname><given-names>HG</given-names></name><name><surname>Schreckenberger</surname><given-names>M</given-names></name><name><surname>Fuss</surname><given-names>G</given-names></name><name><surname>Reith</surname><given-names>W</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Krick</surname><given-names>CM</given-names></name></person-group>
<year>2009</year>
<article-title>Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET</article-title>
<source>Neuroimage</source>
<volume>47</volume>
<fpage>1237</fpage>
<lpage>1243</lpage>
<pub-id pub-id-type="pmid">19497378</pub-id></element-citation></ref><ref id="r91"><label>91</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Behnke</surname><given-names>S</given-names></name><name><surname>Liepelt</surname><given-names>I</given-names></name><name><surname>Schweitzer</surname><given-names>K</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Wollenweber</surname><given-names>F</given-names></name><name><surname>Gaenslen</surname><given-names>A</given-names></name><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Spiegel</surname><given-names>J</given-names></name><name><surname>Godau</surname><given-names>J</given-names></name><name><surname>Huber</surname><given-names>H</given-names></name><name><surname>Srulijes</surname><given-names>K</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Bentele</surname><given-names>M</given-names></name><name><surname>Gasperi</surname><given-names>A</given-names></name><name><surname>Schubert</surname><given-names>T</given-names></name><name><surname>Hiry</surname><given-names>T</given-names></name><name><surname>Probst</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>V</given-names></name><name><surname>Klenk</surname><given-names>J</given-names></name><name><surname>Sawires</surname><given-names>M</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Maetzler</surname><given-names>W</given-names></name><name><surname>Fassbender</surname><given-names>K</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2011</year>
<article-title>Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: A 37-month 3-center study of 1847 older persons</article-title>
<source>Arch Neurol</source>
<volume>68</volume>
<fpage>932</fpage>
<lpage>937</lpage>
<pub-id pub-id-type="pmid">21747034</pub-id></element-citation></ref><ref id="r92"><label>92</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Behnke</surname><given-names>S</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name><name><surname>Godau</surname><given-names>J</given-names></name><name><surname>Lerche</surname><given-names>S</given-names></name><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Liepelt-Scarfone</surname><given-names>I</given-names></name><name><surname>Pausch</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>N</given-names></name><name><surname>Gaenslen</surname><given-names>A</given-names></name><name><surname>Brockmann</surname><given-names>K</given-names></name><name><surname>Srulijes</surname><given-names>K</given-names></name><name><surname>Huber</surname><given-names>H</given-names></name><name><surname>Wurster</surname><given-names>I</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Gasperi</surname><given-names>A</given-names></name><name><surname>Fassbender</surname><given-names>K</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2013</year>
<article-title>Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>28</volume>
<fpage>216</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="pmid">23115051</pub-id></element-citation></ref><ref id="r93"><label>93</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahlknecht</surname><given-names>P</given-names></name><name><surname>Kiechl</surname><given-names>S</given-names></name><name><surname>Stockner</surname><given-names>H</given-names></name><name><surname>Willeit</surname><given-names>J</given-names></name><name><surname>Gasperi</surname><given-names>A</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Seppi</surname><given-names>K</given-names></name></person-group>
<year>2015</year>
<article-title>Predictors for mild parkinsonian signs: A prospective population-based study</article-title>
<source>Parkinsonism Relat Disord</source>
<volume>21</volume>
<fpage>321</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="pmid">25585991</pub-id></element-citation></ref><ref id="r94"><label>94</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sierra</surname><given-names>M</given-names></name><name><surname>S&#x000e1;nchez-Juan</surname><given-names>P</given-names></name><name><surname>Mart&#x000ed;nez-Rodr&#x000ed;guez</surname><given-names>MI</given-names></name><name><surname>Gonz&#x000e1;lez-Aramburu</surname><given-names>I</given-names></name><name><surname>Garc&#x000ed;a-Gorostiaga</surname><given-names>I</given-names></name><name><surname>Quirce</surname><given-names>MR</given-names></name><name><surname>Palacio</surname><given-names>E</given-names></name><name><surname>Carril</surname><given-names>JM</given-names></name><name><surname>Berciano</surname><given-names>J</given-names></name><name><surname>Combarros</surname><given-names>O</given-names></name><name><surname>Infante</surname><given-names>J</given-names></name></person-group>
<year>2013</year>
<article-title>Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease</article-title>
<source>Neurology</source>
<volume>80</volume>
<fpage>621</fpage>
<lpage>626</lpage>
<pub-id pub-id-type="pmid">23325906</pub-id></element-citation></ref><ref id="r95"><label>95</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Trinh</surname><given-names>J</given-names></name><name><surname>Farrer</surname><given-names>M</given-names></name></person-group>
<year>2013</year>
<article-title>Advances in the genetics of Parkinson disease</article-title>
<source>Nat Rev Neurol</source>
<volume>9</volume>
<fpage>445</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="pmid">23857047</pub-id></element-citation></ref><ref id="r96"><label>96</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sidransky</surname><given-names>E</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name><name><surname>Aharon-Peretz</surname><given-names>J</given-names></name><name><surname>Annesi</surname><given-names>G</given-names></name><name><surname>Barbosa</surname><given-names>ER</given-names></name><name><surname>Bar-Shira</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>C-M</given-names></name><name><surname>Clark</surname><given-names>LN</given-names></name><name><surname>Condroyer</surname><given-names>C</given-names></name><name><surname>De Marco</surname><given-names>EV</given-names></name><name><surname>D&#x000fc;rr</surname><given-names>A</given-names></name><name><surname>Eblan</surname><given-names>MJ</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Fung</surname><given-names>H-C</given-names></name><name><surname>Gan-Or</surname><given-names>Z</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Gershoni-Baruch</surname><given-names>R</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name><name><surname>Griffith</surname><given-names>a</given-names></name><name><surname>Gurevich</surname><given-names>T</given-names></name><name><surname>Januario</surname><given-names>C</given-names></name><name><surname>Kropp</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Lee-Chen</surname><given-names>G-J</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Mata</surname><given-names>IF</given-names></name><name><surname>Mirelman</surname><given-names>a</given-names></name><name><surname>Mitsui</surname><given-names>J</given-names></name><name><surname>Mizuta</surname><given-names>I</given-names></name><name><surname>Nicoletti</surname><given-names>G</given-names></name><name><surname>Oliveira</surname><given-names>C</given-names></name><name><surname>Ottman</surname><given-names>R</given-names></name><name><surname>Orr-Urtreger</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>LV</given-names></name><name><surname>Quattrone</surname><given-names>a</given-names></name><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>Rolfs</surname><given-names>a</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Rozenberg</surname><given-names>R</given-names></name><name><surname>Samii</surname><given-names>a</given-names></name><name><surname>Samaddar</surname><given-names>T</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>a</given-names></name><name><surname>Spitz</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>E-K</given-names></name><name><surname>Tayebi</surname><given-names>N</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name><name><surname>Troiano</surname><given-names>AR</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Wittstock</surname><given-names>M</given-names></name><name><surname>Wolfsberg</surname><given-names>TG</given-names></name><name><surname>Wu</surname><given-names>Y-R</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Ziegler</surname><given-names>SG</given-names></name></person-group>
<year>2009</year>
<article-title>Multicenter analysis of glucocerebrosidase mutations in Parkinson&#x02019;s disease</article-title>
<source>N Engl J Med</source>
<volume>361</volume>
<fpage>1651</fpage>
<lpage>1661</lpage>
<pub-id pub-id-type="pmid">19846850</pub-id></element-citation></ref><ref id="r97"><label>97</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anheim</surname><given-names>M</given-names></name><name><surname>Elbaz</surname><given-names>A</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Condroyer</surname><given-names>C</given-names></name><name><surname>Viallet</surname><given-names>F</given-names></name><name><surname>Pollak</surname><given-names>P</given-names></name><name><surname>Bona&#x000ef;ti</surname><given-names>B</given-names></name><name><surname>Bona&#x000ef;ti-Pelli&#x000e9;</surname><given-names>C</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group>
<year>2012</year>
<article-title>Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers</article-title>
<source>Neurology</source>
<volume>78</volume>
<fpage>417</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="pmid">22282650</pub-id></element-citation></ref><ref id="r98"><label>98</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brockmann</surname><given-names>K</given-names></name><name><surname>Srulijes</surname><given-names>K</given-names></name><name><surname>Pflederer</surname><given-names>S</given-names></name><name><surname>Hauser</surname><given-names>A-K</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Maetzler</surname><given-names>W</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name></person-group>
<year>2015</year>
<article-title>GBA-associated Parkinson&#x02019;s disease: Reduced survival and more rapid progression in a prospective longitudinal study</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>407</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="pmid">25448271</pub-id></element-citation></ref><ref id="r99"><label>99</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beavan</surname><given-names>M</given-names></name><name><surname>McNeill</surname><given-names>A</given-names></name><name><surname>Proukakis</surname><given-names>C</given-names></name><name><surname>Hughes</surname><given-names>DA</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Schapira</surname><given-names>AHV</given-names></name></person-group>
<year>2015</year>
<article-title>Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort</article-title>
<source>JAMA Neurol</source>
<volume>72</volume>
<fpage>201</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="pmid">25506732</pub-id></element-citation></ref><ref id="r100"><label>100</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mencacci</surname><given-names>NE</given-names></name><name><surname>Isaias</surname><given-names>IU</given-names></name><name><surname>Reich</surname><given-names>MM</given-names></name><name><surname>Ganos</surname><given-names>C</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Polke</surname><given-names>JM</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Hersheson</surname><given-names>J</given-names></name><name><surname>Stamelou</surname><given-names>M</given-names></name><name><surname>Pittman</surname><given-names>AM</given-names></name><name><surname>Noyce</surname><given-names>AJ</given-names></name><name><surname>Mok</surname><given-names>KY</given-names></name><name><surname>Opladen</surname><given-names>T</given-names></name><name><surname>Kunstmann</surname><given-names>E</given-names></name><name><surname>Hodecker</surname><given-names>S</given-names></name><name><surname>M&#x000fc;nchau</surname><given-names>A</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><name><surname>Samnick</surname><given-names>S</given-names></name><name><surname>Sidle</surname><given-names>K</given-names></name><name><surname>Nanji</surname><given-names>T</given-names></name><name><surname>Sweeney</surname><given-names>MG</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Batla</surname><given-names>A</given-names></name><name><surname>Zecchinelli</surname><given-names>AL</given-names></name><name><surname>Pezzoli</surname><given-names>G</given-names></name><name><surname>Marotta</surname><given-names>G</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name><name><surname>Alegria</surname><given-names>P</given-names></name><name><surname>Krack</surname><given-names>P</given-names></name><name><surname>Cormier-Dequaire</surname><given-names>F</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Lubbe</surname><given-names>SJ</given-names></name><name><surname>Morris</surname><given-names>HR</given-names></name><name><surname>Taba</surname><given-names>P</given-names></name><name><surname>Koks</surname><given-names>S</given-names></name><name><surname>Majounie</surname><given-names>E</given-names></name><name><surname>Raphael Gibbs</surname><given-names>J</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Klebe</surname><given-names>S</given-names></name><name><surname>Bhatia</surname><given-names>KP</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group>
<year>2014</year>
<article-title>Parkinson&#x02019;s disease in GTP cyclohydrolase 1 mutation carriers</article-title>
<source>Brain</source>
<volume>137</volume>
<fpage>2480</fpage>
<lpage>2492</lpage>
<pub-id pub-id-type="pmid">24993959</pub-id></element-citation></ref><ref id="r101"><label>101</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name><name><surname>Hernandez</surname><given-names>DG</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Sheerin</surname><given-names>UM</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>Sim&#x000f3;n-S&#x000e1;nchez</surname><given-names>J</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Sveinbj&#x000f6;rnsd&#x000f3;ttir</surname><given-names>S</given-names></name><name><surname>Stef&#x000e1;nsson</surname><given-names>K</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group>
<year>2011</year>
<article-title>Imputation of sequence variants for identification of genetic risks for Parkinson&#x02019;s disease: A meta-analysis of genome-wide association studies</article-title>
<source>Lancet</source>
<volume>377</volume>
<fpage>641</fpage>
<lpage>649</lpage>
<pub-id pub-id-type="pmid">21292315</pub-id></element-citation></ref><ref id="r102"><label>102</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Lill</surname><given-names>CM</given-names></name><name><surname>Do</surname><given-names>CB</given-names></name><name><surname>Hernandez</surname><given-names>DG</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Kara</surname><given-names>E</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>MF</given-names></name><name><surname>Arepalli</surname><given-names>S</given-names></name><name><surname>Letson</surname><given-names>C</given-names></name><name><surname>Edsall</surname><given-names>C</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Pliner</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><collab>International Parkinson&#x02019;s Disease Genomics Consortium (IPDGC); Parkinson&#x02019;s Study Group (PSG) Parkinson&#x02019;s Research: The Organized GENetics Initiative (PROGENI); 23 and Me; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson&#x02019;s Disease Consortium; Alzheimer Genetic Analysis Group</collab><name><surname>Ikram</surname><given-names>MA</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Hadjigeorgiou</surname><given-names>GM</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Perlmutter</surname><given-names>JS</given-names></name><name><surname>Goate</surname><given-names>A</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Fiske</surname><given-names>B</given-names></name><name><surname>Sutherland</surname><given-names>M</given-names></name><name><surname>Xiromerisiou</surname><given-names>G</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Clark</surname><given-names>LN</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Houlden</surname><given-names>H</given-names></name><name><surname>Payami</surname><given-names>H</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name></person-group>
<year>2014</year>
<article-title>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson&#x02019;s disease</article-title>
<source>Nat Genet</source>
<volume>46</volume>
<fpage>989</fpage>
<lpage>993</lpage>
<pub-id pub-id-type="pmid">25064009</pub-id></element-citation></ref><ref id="r103"><label>103</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lill</surname><given-names>CM</given-names></name><name><surname>Roehr</surname><given-names>JT</given-names></name><name><surname>McQueen</surname><given-names>MB</given-names></name><name><surname>Kavvoura</surname><given-names>FK</given-names></name><name><surname>Bagade</surname><given-names>S</given-names></name><name><surname>Schjeide</surname><given-names>BM</given-names></name><name><surname>Schjeide</surname><given-names>LM</given-names></name><name><surname>Meissner</surname><given-names>E</given-names></name><name><surname>Zauft</surname><given-names>U</given-names></name><name><surname>Allen</surname><given-names>NC</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Schilling</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>KJ</given-names></name><name><surname>Beecham</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Biernacka</surname><given-names>JM</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>DeStefano</surname><given-names>AL</given-names></name><name><surname>Do</surname><given-names>CB</given-names></name><name><surname>Eriksson</surname><given-names>N</given-names></name><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Hamza</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Hill-Burns</surname><given-names>EM</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Latourelle</surname><given-names>JC</given-names></name><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Payami</surname><given-names>H</given-names></name><name><surname>Satake</surname><given-names>W</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name><name><surname>Tung</surname><given-names>JY</given-names></name><name><surname>Vance</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><collab>23andMe Genetic Epidemiology of Parkinson&#x02019;s Disease Consortium; International Parkinson&#x02019;s Disease Genomics Consortium; Parkinson&#x02019;s Disease GWAS Consortium; Wellcome Trust Case Control Consortium 2)</collab><name><surname>Young</surname><given-names>P</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><name><surname>Khoury</surname><given-names>MJ</given-names></name><name><surname>Zipp</surname><given-names>F</given-names></name><name><surname>Lehrach</surname><given-names>H</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name></person-group>
<year>2012</year>
<article-title>Comprehensive research synopsis and systematic meta-analyses in Parkinson&#x02019;s disease genetics: The PDgene database</article-title>
<source>PLoS Genet</source>
<volume>8</volume>
<fpage>4</fpage>
<lpage>13</lpage>
</element-citation></ref><ref id="r104"><label>104</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Escott-Price</surname><given-names>V</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Morris</surname><given-names>HR</given-names></name><name><surname>Lubbe</surname><given-names>S</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Williams</surname><given-names>NM</given-names></name></person-group>
<year>2015</year>
<article-title>Polygenic risk of Parkinson disease is correlated with disease age at onset</article-title>
<source>Ann Neurol</source>
<volume>77</volume>
<fpage>582</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="pmid">25773351</pub-id></element-citation></ref><ref id="r105"><label>105</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>McLean</surname><given-names>CY</given-names></name><name><surname>Rick</surname><given-names>J</given-names></name><name><surname>Eberly</surname><given-names>S</given-names></name><name><surname>Hutten</surname><given-names>SJ</given-names></name><name><surname>Gwinn</surname><given-names>K</given-names></name><name><surname>Sutherland</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>NM</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>TR</given-names></name><name><surname>Nicolas</surname><given-names>A</given-names></name><name><surname>Keller</surname><given-names>MF</given-names></name><name><surname>Molony</surname><given-names>C</given-names></name><name><surname>Gibbs</surname><given-names>JR</given-names></name><name><surname>Chen-Plotkin</surname><given-names>A</given-names></name><name><surname>Suh</surname><given-names>E</given-names></name><name><surname>Letson</surname><given-names>C</given-names></name><name><surname>Fiandaca</surname><given-names>MS</given-names></name><name><surname>Mapstone</surname><given-names>M</given-names></name><name><surname>Federoff</surname><given-names>HJ</given-names></name><name><surname>Noyce</surname><given-names>AJ</given-names></name><name><surname>Morris</surname><given-names>H</given-names></name><name><surname>Van Deerlin</surname><given-names>VM</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Zabetian</surname><given-names>C</given-names></name><name><surname>Hernandez</surname><given-names>DG</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Mullins</surname><given-names>M</given-names></name><name><surname>Conley</surname><given-names>ED</given-names></name><name><surname>Northover</surname><given-names>CA</given-names></name><name><surname>Frasier</surname><given-names>M5</given-names></name><name><surname>Marek</surname><given-names>K</given-names></name><name><surname>Day-Williams</surname><given-names>AG</given-names></name><name><surname>Stone</surname><given-names>DJ</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><collab>Parkinson&#x02019;s Disease Biomarkers Program and Parkinson&#x02019;s Progression Marker Initiative investigators</collab></person-group>
<year>2015</year>
<article-title>Diagnosis of Parkinson&#x02019;s disease on the basis of clinical and genetic classification: A population-based modelling study</article-title>
<source>Lancet Neurol</source>
<volume>14</volume>
<fpage>1002</fpage>
<lpage>1009</lpage>
<pub-id pub-id-type="pmid">26271532</pub-id></element-citation></ref><ref id="r106"><label>106</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pankratz</surname><given-names>N</given-names></name><name><surname>Beecham</surname><given-names>GW</given-names></name><name><surname>Destefano</surname><given-names>AL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Hamza</surname><given-names>TH</given-names></name><name><surname>Hung</surname><given-names>AY</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Ivinson</surname><given-names>AJ</given-names></name><name><surname>Krainc</surname><given-names>D</given-names></name><name><surname>Latourelle</surname><given-names>JC</given-names></name><name><surname>Clark</surname><given-names>LN</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>OA</given-names></name><name><surname>Scherzer</surname><given-names>CR</given-names></name><name><surname>Simon</surname><given-names>DK</given-names></name><name><surname>Tanner</surname><given-names>C</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name><name><surname>Wszolek</surname><given-names>ZK</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Myers</surname><given-names>RH</given-names></name><name><surname>Payami</surname><given-names>H</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Foroud</surname><given-names>T</given-names></name></person-group>
<year>2012</year>
<article-title>Meta-analysis of Parkinson&#x02019;s Disease: Identification of a novel locus, RIT2</article-title>
<source>Ann Neurol</source>
<volume>71</volume>
<fpage>370</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="pmid">22451204</pub-id></element-citation></ref><ref id="r107"><label>107</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Castrioto</surname><given-names>A</given-names></name><name><surname>Chiasserini</surname><given-names>D</given-names></name><name><surname>Persichetti</surname><given-names>E</given-names></name><name><surname>Tambasco</surname><given-names>N</given-names></name><name><surname>El-Agnaf</surname><given-names>O</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name></person-group>
<year>2013</year>
<article-title>Cerebrospinal fluid biomarkers in Parkinson disease</article-title>
<source>Nat Rev Neurol</source>
<volume>9</volume>
<fpage>131</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="pmid">23419373</pub-id></element-citation></ref><ref id="r108"><label>108</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Del Campo</surname><given-names>M</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Bertolotto</surname><given-names>A</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Simonsen</surname><given-names>AH</given-names></name><name><surname>Kapaki</surname><given-names>E</given-names></name><name><surname>Kruse</surname><given-names>N</given-names></name><name><surname>Le Bastard</surname><given-names>N</given-names></name><name><surname>Lehmann</surname><given-names>S</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Perret-Liaudet</surname><given-names>A</given-names></name><name><surname>S&#x000e1;ez-Valero</surname><given-names>J</given-names></name><name><surname>Saka</surname><given-names>E</given-names></name><name><surname>Urbani</surname><given-names>A</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Verbeek</surname><given-names>M</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Teunissen</surname><given-names>C</given-names></name></person-group>
<year>2012</year>
<article-title>Recommendations to standardize preanalytical confounding factors in Alzheimer&#x02019;s and Parkinson&#x02019;s disease cerebrospinal fluid biomarkers: An update</article-title>
<source>Biomark Med</source>
<volume>6</volume>
<fpage>419</fpage>
<lpage>430</lpage>
<pub-id pub-id-type="pmid">22917144</pub-id></element-citation></ref><ref id="r109"><label>109</label><element-citation publication-type="journal">
<person-group person-group-type="author"><collab>Parkinson ProgressionMarker, Initiative</collab></person-group>
<year>2011</year>
<article-title>The Parkinson Progression Marker Initiative (PPMI)</article-title>
<source>Prog Neurobiol</source>
<volume>95</volume>
<fpage>629</fpage>
<lpage>635</lpage>
<pub-id pub-id-type="pmid">21930184</pub-id></element-citation></ref><ref id="r110"><label>110</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>JH</given-names></name><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Chen-Plotkin</surname><given-names>AS</given-names></name><name><surname>Siderowf</surname><given-names>A</given-names></name><name><surname>Caspell</surname><given-names>C</given-names></name><name><surname>Coffey</surname><given-names>CS</given-names></name><name><surname>Walig&#x000f3;rska</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>P</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Frasier</surname><given-names>M</given-names></name><name><surname>Marek</surname><given-names>K</given-names></name><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>Jennings</surname><given-names>D</given-names></name><name><surname>Simuni</surname><given-names>T</given-names></name><name><surname>Tanner</surname><given-names>CM</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Toga</surname><given-names>AW</given-names></name><name><surname>Chowdhury</surname><given-names>S</given-names></name><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><collab>Parkinson&#x02019;s Progression Markers Initiative</collab></person-group>
<year>2013</year>
<article-title>Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease</article-title>
<source>JAMA Neurol</source>
<volume>70</volume>
<fpage>1277</fpage>
<lpage>1287</lpage>
<pub-id pub-id-type="pmid">23979011</pub-id></element-citation></ref><ref id="r111"><label>111</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Nie</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name></person-group>
<year>2015</year>
<article-title>Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson&#x02019;s disease diagnosis: A systematic review and meta-analysis</article-title>
<source>Int J Neurosci</source>
<volume>125</volume>
<fpage>645</fpage>
<lpage>654</lpage>
<pub-id pub-id-type="pmid">25202803</pub-id></element-citation></ref><ref id="r112"><label>112</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Petzold</surname><given-names>M</given-names></name><name><surname>Magdalinou</surname><given-names>N</given-names></name></person-group>
<year>2014</year>
<article-title>Cerebrospinal fluid &#x003b1;-synuclein levels in Parkinson&#x02019;s disease&#x02013;changed or unchanged? Eur</article-title>
<source>J Neurol</source>
<volume>21</volume>
<fpage>365</fpage>
<lpage>367</lpage>
</element-citation></ref><ref id="r113"><label>113</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Hancock</surname><given-names>AM</given-names></name><name><surname>Ginghina</surname><given-names>C</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Yearout</surname><given-names>D</given-names></name><name><surname>Chung</surname><given-names>KA</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>
<year>2010</year>
<article-title>Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson&#x02019;s disease</article-title>
<source>Neurosci Lett</source>
<volume>480</volume>
<fpage>78</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">20540987</pub-id></element-citation></ref><ref id="r114"><label>114</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Qiang</surname><given-names>JK</given-names></name><name><surname>Wong</surname><given-names>YC</given-names></name><name><surname>Siderowf</surname><given-names>A</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Xie</surname><given-names>SX</given-names></name><name><surname>Lee</surname><given-names>VMY</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Yearout</surname><given-names>D</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Mendick</surname><given-names>S</given-names></name><name><surname>Jennings</surname><given-names>D</given-names></name><name><surname>Zabetian</surname><given-names>C</given-names></name><name><surname>Marek</surname><given-names>K</given-names></name><name><surname>Chen-Plotkin</surname><given-names>AS</given-names></name></person-group>
<year>2013</year>
<article-title>Plasma apolipoprotein A1 as a biomarker for Parkinson disease</article-title>
<source>Ann Neurol</source>
<volume>74</volume>
<fpage>119</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="pmid">23447138</pub-id></element-citation></ref><ref id="r115"><label>115</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Swanson</surname><given-names>CR</given-names></name><name><surname>Berlyand</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>SX</given-names></name><name><surname>Alcalay</surname><given-names>RN</given-names></name><name><surname>Chahine</surname><given-names>LM</given-names></name><name><surname>Chen-Plotkin</surname><given-names>AS</given-names></name></person-group>
<year>2015</year>
<article-title>Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson&#x02019;s disease patients</article-title>
<source>Mov Disord</source>
<pub-id pub-id-type="doi">10.1002/mds.26290</pub-id>
</element-citation></ref><ref id="r116"><label>116</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>R-M</given-names></name><name><surname>Lin</surname><given-names>M-S</given-names></name><name><surname>Lin</surname><given-names>J-W</given-names></name><name><surname>Chang</surname><given-names>C-H</given-names></name><name><surname>Lai</surname><given-names>M-S</given-names></name></person-group>
<year>2013</year>
<article-title>Discontinuation of statin therapy associates with Parkinson disease: A population-based study</article-title>
<source>Neurology</source>
<volume>81</volume>
<fpage>410</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="pmid">23884037</pub-id></element-citation></ref><ref id="r117"><label>117</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Umbach</surname><given-names>DM</given-names></name><name><surname>Lichtenstein</surname><given-names>ML</given-names></name><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Mailman</surname><given-names>RB</given-names></name><name><surname>Mosley</surname><given-names>TH</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group>
<year>2015</year>
<article-title>Statins, plasma cholesterol, and risk of Parkinson&#x02019;s disease: A prospective study</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>552</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="pmid">25639598</pub-id></element-citation></ref><ref id="r118"><label>118</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Antikainen</surname><given-names>R</given-names></name><name><surname>Jousilahti</surname><given-names>P</given-names></name><name><surname>Kivipelto</surname><given-names>M</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name></person-group>
<year>2008</year>
<article-title>Total cholesterol and the risk of Parkinson disease</article-title>
<source>Neurology</source>
<volume>70</volume>
<fpage>1972</fpage>
<lpage>1979</lpage>
<pub-id pub-id-type="pmid">18401018</pub-id></element-citation></ref><ref id="r119"><label>119</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Abbott</surname><given-names>RD</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Mailman</surname><given-names>RB</given-names></name><name><surname>Ross</surname><given-names>GW</given-names></name></person-group>
<year>2008</year>
<article-title>Low LDL cholesterol and increased risk of Parkinson&#x02019;s disease: Prospective results from Honolulu-Asia Aging Study</article-title>
<source>Mov Disord</source>
<volume>23</volume>
<fpage>1013</fpage>
<lpage>1018</lpage>
<pub-id pub-id-type="pmid">18381649</pub-id></element-citation></ref><ref id="r120"><label>120</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serafin</surname><given-names>A</given-names></name><name><surname>Foco</surname><given-names>L</given-names></name><name><surname>Zanigni</surname><given-names>S</given-names></name><name><surname>Blankenburg</surname><given-names>H</given-names></name><name><surname>Picard</surname><given-names>A</given-names></name><name><surname>Zanon</surname><given-names>A</given-names></name><name><surname>Giannini</surname><given-names>G</given-names></name><name><surname>Pichler</surname><given-names>I</given-names></name><name><surname>Facheris</surname><given-names>MF</given-names></name><name><surname>Cortelli</surname><given-names>P</given-names></name><name><surname>Pramstaller</surname><given-names>PP</given-names></name><name><surname>Hicks</surname><given-names>AA</given-names></name><name><surname>Domingues</surname><given-names>FS</given-names></name><name><surname>Schwienbacher</surname><given-names>C</given-names></name></person-group>
<year>2015</year>
<article-title>Overexpression of blood microRNAs 103a, 30b, and 29a in L-dopa-treated patients with PD</article-title>
<source>Neurology</source>
<volume>84</volume>
<fpage>645</fpage>
<lpage>653</lpage>
<pub-id pub-id-type="pmid">25596505</pub-id></element-citation></ref><ref id="r121"><label>121</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khoo</surname><given-names>SK</given-names></name><name><surname>Petillo</surname><given-names>D</given-names></name><name><surname>Kang</surname><given-names>UJ</given-names></name><name><surname>Resau</surname><given-names>JH</given-names></name><name><surname>Berryhill</surname><given-names>B</given-names></name><name><surname>Linder</surname><given-names>J</given-names></name><name><surname>Forsgren</surname><given-names>L</given-names></name><name><surname>Neuman</surname><given-names>LA</given-names></name><name><surname>Tan</surname><given-names>AC</given-names></name></person-group>
<year>2012</year>
<article-title>Plasma-based circulating MicroRNA biomarkers for Parkinson&#x02019;s disease</article-title>
<source>J Parkinsons Dis</source>
<volume>2</volume>
<fpage>321</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="pmid">23938262</pub-id></element-citation></ref><ref id="r122"><label>122</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKhann</surname><given-names>GM</given-names></name></person-group>
<year>2011</year>
<article-title>Changing concepts of Alzheimerdisease</article-title>
<source>JAMA</source>
<volume>305</volume>
<fpage>2458</fpage>
<lpage>2459</lpage>
<pub-id pub-id-type="pmid">21673298</pub-id></element-citation></ref><ref id="r123"><label>123</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>
<year>2012</year>
<article-title>Biochemical premotor biomarkers for Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>644</fpage>
<lpage>650</lpage>
<pub-id pub-id-type="pmid">22508282</pub-id></element-citation></ref><ref id="r124"><label>124</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>KA</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Baird</surname><given-names>G</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Hancock</surname><given-names>AM</given-names></name><name><surname>Hwang</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Bradner</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>UJ</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>
<year>2010</year>
<article-title>DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson&#x02019;s disease</article-title>
<source>Brain</source>
<volume>133</volume>
<fpage>713</fpage>
<lpage>726</lpage>
<pub-id pub-id-type="pmid">20157014</pub-id></element-citation></ref><ref id="r125"><label>125</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Bradner</surname><given-names>J</given-names></name><name><surname>Hancock</surname><given-names>AM</given-names></name><name><surname>Chung</surname><given-names>KA</given-names></name><name><surname>Quinn</surname><given-names>JF</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Kim</surname><given-names>HM</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Ginghina</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>UJ</given-names></name><name><surname>Cain</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Aasly</surname><given-names>J</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>
<year>2011</year>
<article-title>Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression</article-title>
<source>Ann Neurol</source>
<volume>69</volume>
<fpage>570</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="pmid">21400565</pub-id></element-citation></ref><ref id="r126"><label>126</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Locascio</surname><given-names>JJ</given-names></name><name><surname>Schulz-Schaeffer</surname><given-names>W</given-names></name><name><surname>Sixel-D&#x000f6;ring</surname><given-names>F</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name></person-group>
<year>2011</year>
<article-title>&#x003b1;-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study</article-title>
<source>Lancet Neurol</source>
<volume>10</volume>
<fpage>230</fpage>
<lpage>240</lpage>
<pub-id pub-id-type="pmid">21317042</pub-id></element-citation></ref><ref id="r127"><label>127</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van Dijk</surname><given-names>KD</given-names></name><name><surname>Bidinosti</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name><name><surname>Raijmakers</surname><given-names>P</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name><name><surname>van de Berg</surname><given-names>WDJ</given-names></name></person-group>
<year>2014</year>
<article-title>Reduced &#x003b1;-synuclein levels in cerebrospinal fluid in Parkinson&#x02019;s disease are unrelated to clinical and imaging measures of disease severity</article-title>
<source>Eur J Neurol</source>
<volume>21</volume>
<fpage>388</fpage>
<lpage>394</lpage>
<pub-id pub-id-type="pmid">23631635</pub-id></element-citation></ref><ref id="r128"><label>128</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mollenhauer</surname><given-names>B</given-names></name><name><surname>Trautmann</surname><given-names>E</given-names></name><name><surname>Taylor</surname><given-names>P</given-names></name><name><surname>Manninger</surname><given-names>P</given-names></name><name><surname>Sixel-D&#x000f6;ring</surname><given-names>F</given-names></name><name><surname>Ebentheuer</surname><given-names>J</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name></person-group>
<year>2013</year>
<article-title>Total CSF &#x003b1;-synuclein is lower in de novo Parkinson patients than in healthy subjects</article-title>
<source>Neurosci Lett</source>
<volume>532</volume>
<fpage>44</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="pmid">23149132</pub-id></element-citation></ref><ref id="r129"><label>129</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>KA</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Srulijes</surname><given-names>K</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM-Y</given-names></name><name><surname>Siderowf</surname><given-names>AD</given-names></name><name><surname>Hurtig</surname><given-names>H</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>Schiess</surname><given-names>MC</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Goldstein</surname><given-names>DS</given-names></name><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Cain</surname><given-names>KC</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>
<year>2012</year>
<article-title>Phosphorylated alpha-synuclein in Parkinson&#x02019;s disease</article-title>
<source>Sci Transl Med</source>
<volume>4</volume>
<comment>121ra20-121ra20</comment>
</element-citation></ref><ref id="r130"><label>130</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tokuda</surname><given-names>T</given-names></name><name><surname>Qureshi</surname><given-names>MM</given-names></name><name><surname>Ardah</surname><given-names>MT</given-names></name><name><surname>Varghese</surname><given-names>S</given-names></name><name><surname>Shehab</surname><given-names>SA</given-names></name><name><surname>Kasai</surname><given-names>T</given-names></name><name><surname>Ishigami</surname><given-names>N</given-names></name><name><surname>Tamaoka</surname><given-names>a</given-names></name><name><surname>Nakagawa</surname><given-names>M</given-names></name><name><surname>El-Agnaf</surname><given-names>OM</given-names></name></person-group>
<year>2010</year>
<article-title>Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease</article-title>
<source>Neurology</source>
<volume>75</volume>
<fpage>1766</fpage>
<lpage>1772</lpage>
<pub-id pub-id-type="pmid">20962290</pub-id></element-citation></ref><ref id="r131"><label>131</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Gibbons</surname><given-names>CH</given-names></name><name><surname>Lafo</surname><given-names>J</given-names></name><name><surname>Freeman</surname><given-names>BSR</given-names></name></person-group>
<year>2013</year>
<article-title>&#x003b1;-Synuclein in cutaneous autonomic nerves</article-title>
<source>Neurology</source>
<volume>81</volume>
<fpage>1604</fpage>
<lpage>1610</lpage>
<pub-id pub-id-type="pmid">24089386</pub-id></element-citation></ref><ref id="r132"><label>132</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doppler</surname><given-names>K</given-names></name><name><surname>Ebert</surname><given-names>S</given-names></name><name><surname>&#x000dc;&#x000e7;eyler</surname><given-names>N</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Ebentheuer</surname><given-names>J</given-names></name><name><surname>Volkmann</surname><given-names>J</given-names></name><name><surname>Sommer</surname><given-names>C</given-names></name></person-group>
<year>2014</year>
<article-title>Cutaneous neuropathy in Parkinson&#x02019;s disease: A window into brain pathology</article-title>
<source>Acta Neuropathol</source>
<volume>128</volume>
<fpage>99</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="pmid">24788821</pub-id></element-citation></ref><ref id="r133"><label>133</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donadio</surname><given-names>V</given-names></name><name><surname>Incensi</surname><given-names>A</given-names></name><name><surname>Leta</surname><given-names>V</given-names></name><name><surname>Giannoccaro</surname><given-names>MP</given-names></name><name><surname>Scaglione</surname><given-names>C</given-names></name><name><surname>Martinelli</surname><given-names>P</given-names></name><name><surname>Capellari</surname><given-names>S</given-names></name><name><surname>Avoni</surname><given-names>P</given-names></name><name><surname>Baruzzi</surname><given-names>A</given-names></name><name><surname>Liguori</surname><given-names>R</given-names></name></person-group>
<year>2014</year>
<article-title>Skin nerve a-synuclein deposits A biomarker for idiopathic Parkinson disease</article-title>
<source>Neurology</source>
<volume>82</volume>
<fpage>1362</fpage>
<lpage>1369</lpage>
<pub-id pub-id-type="pmid">24634456</pub-id></element-citation></ref><ref id="r134"><label>134</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Dugger</surname><given-names>BN</given-names></name><name><surname>Hinni</surname><given-names>ML</given-names></name><name><surname>Lott</surname><given-names>DG</given-names></name><name><surname>Driver-Dunckley</surname><given-names>E</given-names></name><name><surname>Hidalgo</surname><given-names>J</given-names></name><name><surname>Henry-Watson</surname><given-names>J</given-names></name><name><surname>Serrano</surname><given-names>G</given-names></name><name><surname>Sue</surname><given-names>LI</given-names></name><name><surname>Nagel</surname><given-names>T</given-names></name><name><surname>Duffy</surname><given-names>A</given-names></name><name><surname>Shill</surname><given-names>HA</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name></person-group>
<year>2014</year>
<article-title>Submandibular gland needle biopsy for the diagnosis of Parkinson disease</article-title>
<source>Neurology</source>
<volume>82</volume>
<fpage>858</fpage>
<lpage>864</lpage>
<pub-id pub-id-type="pmid">24500652</pub-id></element-citation></ref><ref id="r135"><label>135</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Devic</surname><given-names>I</given-names></name><name><surname>Hwang</surname><given-names>H</given-names></name><name><surname>Edgar</surname><given-names>JS</given-names></name><name><surname>Izutsu</surname><given-names>K</given-names></name><name><surname>Presland</surname><given-names>R</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Goodlett</surname><given-names>DR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Armaly</surname><given-names>J</given-names></name><name><surname>Tumas</surname><given-names>V</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group>
<year>2011</year>
<article-title>Salivary alpha-synuclein and DJ-1: Potential biomarkers for Parkinson&#x02019;s disease</article-title>
<source>Brain</source>
<volume>134</volume>
<issue>Pt 7</issue>
<fpage>e178</fpage>
<pub-id pub-id-type="pmid">21349902</pub-id></element-citation></ref><ref id="r136"><label>136</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Schneider</surname><given-names>SA</given-names></name><name><surname>Boettner</surname><given-names>M</given-names></name><name><surname>Alexoudi</surname><given-names>A</given-names></name><name><surname>Zorenkov</surname><given-names>D</given-names></name><name><surname>Deuschl</surname><given-names>G</given-names></name><name><surname>Wedel</surname><given-names>T</given-names></name></person-group>
<year>2015</year>
<article-title>Can we use peripheral tissue biopsies to diagnose Parkinson&#x02019;s disease? A review of the literature</article-title>
<source>Eur J Neurol</source>
<pub-id pub-id-type="doi">10.1111/ene.12753</pub-id>
</element-citation></ref><ref id="r137"><label>137</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lebouvier</surname><given-names>T</given-names></name><name><surname>Neunlist</surname><given-names>M</given-names></name><name><surname>des Varannes</surname><given-names>SB</given-names></name><name><surname>Coron</surname><given-names>E</given-names></name><name><surname>Drouard</surname><given-names>A</given-names></name><name><surname>N&#x02019;Guyen</surname><given-names>JM</given-names></name><name><surname>Chaumette</surname><given-names>T</given-names></name><name><surname>Tasselli</surname><given-names>M</given-names></name><name><surname>Paillusson</surname><given-names>S</given-names></name><name><surname>Flamand</surname><given-names>M</given-names></name><name><surname>Galmiche</surname><given-names>JP</given-names></name><name><surname>Damier</surname><given-names>P</given-names></name><name><surname>Derkinderen</surname><given-names>P</given-names></name></person-group>
<year>2010</year>
<article-title>Colonic biopsies to assess the neuropathology of Parkinson&#x02019;s disease and its relationship with symptoms</article-title>
<source>PLoS One</source>
<volume>5</volume>
<fpage>1</fpage>
<lpage>9</lpage>
</element-citation></ref><ref id="r138"><label>138</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pouclet</surname><given-names>H</given-names></name><name><surname>Lebouvier</surname><given-names>T</given-names></name><name><surname>Coron</surname><given-names>E</given-names></name><name><surname>Des Varannes</surname><given-names>SB</given-names></name><name><surname>Neunlist</surname><given-names>M</given-names></name><name><surname>Derkinderen</surname><given-names>P</given-names></name></person-group>
<year>2012</year>
<article-title>A comparison between colonic submucosa and mucosa to detect Lewy pathology in Parkinson&#x02019;s disease</article-title>
<source>Neurogastroenterol Motil</source>
<volume>24</volume>
<fpage>202</fpage>
<lpage>205</lpage>
</element-citation></ref><ref id="r139"><label>139</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Visanji</surname><given-names>NP</given-names></name><name><surname>Marras</surname><given-names>C</given-names></name><name><surname>Kern</surname><given-names>DS</given-names></name><name><surname>Al Dakheel</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>LWC</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Hazrati</surname><given-names>L-N</given-names></name></person-group>
<year>2015</year>
<article-title>Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease</article-title>
<source>Neurology</source>
<volume>84</volume>
<fpage>609</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="pmid">25589666</pub-id></element-citation></ref><ref id="r140"><label>140</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Sprenger</surname><given-names>F</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Navarro-Otano</surname><given-names>J</given-names></name><name><surname>Offner</surname><given-names>F</given-names></name><name><surname>Vilas</surname><given-names>D</given-names></name><name><surname>Valladeoriola</surname><given-names>F</given-names></name><name><surname>Pont-Sunyer</surname><given-names>C</given-names></name><name><surname>Aldecoa</surname><given-names>I</given-names></name><name><surname>Gaig</surname><given-names>C</given-names></name><name><surname>Gines</surname><given-names>A</given-names></name><name><surname>Cuatrecases</surname><given-names>M</given-names></name><name><surname>Hogl</surname><given-names>B</given-names></name><name><surname>Frauscher</surname><given-names>B</given-names></name><name><surname>Iranzo</surname><given-names>A</given-names></name><name><surname>Wenning</surname><given-names>GK</given-names></name><name><surname>Vogel</surname><given-names>W</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name></person-group>
<year>2015</year>
<article-title>Enteric nervous system alpha-synuclein immunoreactivity in idopathic REM sleep behavior disorder</article-title>
<source>Neurology</source>
<comment>Oct 16. pii:10.1212/WNL.0000000000002126. [Epub ahead of print]</comment>
</element-citation></ref><ref id="r141"><label>141</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>S&#x000e1;nchez-Ferro</surname><given-names>&#x000c1;</given-names></name><name><surname>R&#x000e1;bano</surname><given-names>A</given-names></name><name><surname>Catal&#x000e1;n</surname><given-names>MJ</given-names></name><name><surname>Rodr&#x000ed;guez-Valc&#x000e1;rcel</surname><given-names>FC</given-names></name><name><surname>Fern&#x000e1;ndez D&#x000ed;ez</surname><given-names>S</given-names></name><name><surname>Herreros-Rodr&#x000ed;guez</surname><given-names>J</given-names></name><name><surname>Garc&#x000ed;a-Cobos</surname><given-names>E</given-names></name><name><surname>&#x000c1;lvarez-Santullano</surname><given-names>MM</given-names></name><name><surname>L&#x000f3;pez-Manzanares</surname><given-names>L</given-names></name><name><surname>Mosqueira</surname><given-names>AJ</given-names></name><name><surname>Vela Desojo</surname><given-names>L</given-names></name><name><surname>L&#x000f3;pez-Lozano</surname><given-names>JJ</given-names></name><name><surname>L&#x000f3;pez-Vald&#x000e1;s</surname><given-names>E</given-names></name><name><surname>S&#x000e1;nchez-S&#x000e1;nchez</surname><given-names>R</given-names></name><name><surname>Molina-Arjona</surname><given-names>JA</given-names></name></person-group>
<year>2015</year>
<article-title>gastric detection of &#x003b1;-synuclein inclusions in Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>517</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="pmid">25113060</pub-id></element-citation></ref><ref id="r142"><label>142</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hilton</surname><given-names>D</given-names></name><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Kirk</surname><given-names>L</given-names></name><name><surname>Edwards</surname><given-names>P</given-names></name><name><surname>Potter</surname><given-names>R</given-names></name><name><surname>Zajicek</surname><given-names>J</given-names></name><name><surname>Broughton</surname><given-names>E</given-names></name><name><surname>Hagan</surname><given-names>H</given-names></name><name><surname>Carroll</surname><given-names>C</given-names></name></person-group>
<year>2014</year>
<article-title>Accumulation of &#x003b1;-synuclein in the bowel of patients in the pre-clinical phase of Parkinson&#x02019;s disease</article-title>
<source>Acta Neuropathol</source>
<volume>127</volume>
<fpage>235</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="pmid">24240814</pub-id></element-citation></ref><ref id="r143"><label>143</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shannon</surname><given-names>KM</given-names></name><name><surname>Keshavarzian</surname><given-names>A</given-names></name><name><surname>Dodiya</surname><given-names>HB</given-names></name><name><surname>Jakate</surname><given-names>S</given-names></name><name><surname>Kordower</surname><given-names>JH</given-names></name></person-group>
<year>2012</year>
<article-title>Is alpha-synuclein in the colon a biomarker for premotor Parkinson&#x02019;s Disease? Evidence from 3 cases</article-title>
<source>Mov Disord</source>
<volume>27</volume>
<fpage>716</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="pmid">22550057</pub-id></element-citation></ref><ref id="r144"><label>144</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>B&#x000f6;ttner</surname><given-names>M</given-names></name><name><surname>Zorenkov</surname><given-names>D</given-names></name><name><surname>Hellwig</surname><given-names>I</given-names></name><name><surname>Barrenschee</surname><given-names>M</given-names></name><name><surname>Harde</surname><given-names>J</given-names></name><name><surname>Fricke</surname><given-names>T</given-names></name><name><surname>Deuschl</surname><given-names>G</given-names></name><name><surname>Egberts</surname><given-names>J-H</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Fritscher-Ravens</surname><given-names>A</given-names></name><name><surname>Arlt</surname><given-names>A</given-names></name><name><surname>Wedel</surname><given-names>T</given-names></name></person-group>
<year>2012</year>
<article-title>Expression pattern and localization of alpha-synuclein in the human enteric nervous system</article-title>
<source>Neurobiol Dis</source>
<volume>48</volume>
<fpage>474</fpage>
<lpage>480</lpage>
<pub-id pub-id-type="pmid">22850485</pub-id></element-citation></ref><ref id="r145"><label>145</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Folgoas</surname><given-names>E</given-names></name><name><surname>Lebouvier</surname><given-names>T</given-names></name><name><surname>Leclair-Visonneau</surname><given-names>L</given-names></name><name><surname>Cersosimo</surname><given-names>M-G</given-names></name><name><surname>Barthelaix</surname><given-names>A</given-names></name><name><surname>Derkinderen</surname><given-names>P</given-names></name><name><surname>Letournel</surname><given-names>F</given-names></name></person-group>
<year>2013</year>
<article-title>Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology</article-title>
<source>Neurosci Lett</source>
<volume>551</volume>
<fpage>62</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="pmid">23880024</pub-id></element-citation></ref><ref id="r146"><label>146</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>White</surname><given-names>CL</given-names></name><name><surname>Hladik</surname><given-names>CL</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Connor</surname><given-names>DJ</given-names></name><name><surname>Shill</surname><given-names>HA</given-names></name><name><surname>Sue</surname><given-names>LI</given-names></name><name><surname>Sasse</surname><given-names>J</given-names></name><name><surname>Bachalakuri</surname><given-names>J</given-names></name><name><surname>Henry-Watson</surname><given-names>J</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name></person-group>
<year>2009</year>
<article-title>Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders</article-title>
<source>Acta Neuropathol</source>
<volume>117</volume>
<fpage>169</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="pmid">18982334</pub-id></element-citation></ref><ref id="r147"><label>147</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Witt</surname><given-names>M</given-names></name><name><surname>Bormann</surname><given-names>K</given-names></name><name><surname>Gudziol</surname><given-names>V</given-names></name><name><surname>Pehlke</surname><given-names>K</given-names></name><name><surname>Barth</surname><given-names>K</given-names></name><name><surname>Minovi</surname><given-names>A</given-names></name><name><surname>H&#x000e4;hner</surname><given-names>A</given-names></name><name><surname>Reichmann</surname><given-names>H</given-names></name><name><surname>Hummel</surname><given-names>T</given-names></name></person-group>
<year>2009</year>
<article-title>Biopsies of olfactory epithelium in patients with Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>24</volume>
<fpage>906</fpage>
<lpage>914</lpage>
<pub-id pub-id-type="pmid">19205070</pub-id></element-citation></ref><ref id="r148"><label>148</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheperjans</surname><given-names>F</given-names></name><name><surname>Aho</surname><given-names>V</given-names></name><name><surname>Pereira</surname><given-names>PAB</given-names></name><name><surname>Koskinen</surname><given-names>K</given-names></name><name><surname>Paulin</surname><given-names>L</given-names></name><name><surname>Pekkonen</surname><given-names>E</given-names></name><name><surname>Haapaniemi</surname><given-names>E</given-names></name><name><surname>Kaakkola</surname><given-names>S</given-names></name><name><surname>Eerola-Rautio</surname><given-names>J</given-names></name><name><surname>Pohja</surname><given-names>M</given-names></name><name><surname>Kinnunen</surname><given-names>E</given-names></name><name><surname>Murros</surname><given-names>K</given-names></name><name><surname>Auvinen</surname><given-names>P</given-names></name></person-group>
<year>2015</year>
<article-title>Gut microbiota are related to Parkinson&#x02019;s disease and clinical phenotype</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>350</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="pmid">25476529</pub-id></element-citation></ref><ref id="r149"><label>149</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keshavarzian</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>SJ</given-names></name><name><surname>Engen</surname><given-names>PA</given-names></name><name><surname>Voigt</surname><given-names>RM</given-names></name><name><surname>Naqib</surname><given-names>A</given-names></name><name><surname>Forsyth</surname><given-names>CB</given-names></name><name><surname>Mutlu</surname><given-names>E</given-names></name><name><surname>Shannon</surname><given-names>KM</given-names></name></person-group>
<year>2015</year>
<article-title>Colonic bacterial composition in Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>1351</fpage>
<lpage>1360</lpage>
<pub-id pub-id-type="pmid">26179554</pub-id></element-citation></ref><ref id="r150"><label>150</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheperjans</surname><given-names>F</given-names></name><name><surname>Pekkonen</surname><given-names>E</given-names></name><name><surname>Kaakkola</surname><given-names>S</given-names></name><name><surname>Auvinen</surname><given-names>P</given-names></name></person-group>
<year>2015</year>
<article-title>Linking smoking, coffee, urate, and Parkinson&#x02019;s disease - a role for gut microbiota?</article-title>
<source>J Parkinsons Dis</source>
<volume>5</volume>
<fpage>255</fpage>
<lpage>262</lpage>
<pub-id pub-id-type="pmid">25882059</pub-id></element-citation></ref><ref id="r151"><label>151</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angot</surname><given-names>E</given-names></name><name><surname>Steiner</surname><given-names>JA</given-names></name><name><surname>Hansen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Brundin</surname><given-names>P</given-names></name></person-group>
<year>2010</year>
<article-title>Are synucleinopathies prion-like disorders?</article-title>
<source>Lancet Neurol</source>
<volume>9</volume>
<fpage>1128</fpage>
<lpage>1138</lpage>
<pub-id pub-id-type="pmid">20846907</pub-id></element-citation></ref><ref id="r152"><label>152</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woerman</surname><given-names>AL</given-names></name><name><surname>St&#x000f6;hr</surname><given-names>J</given-names></name><name><surname>Aoyagi</surname><given-names>A</given-names></name><name><surname>Rampersaud</surname><given-names>R</given-names></name><name><surname>Krejciova</surname><given-names>Z</given-names></name><name><surname>Watts</surname><given-names>JC</given-names></name><name><surname>Ohyama</surname><given-names>T</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Widjaja</surname><given-names>K</given-names></name><name><surname>Oehler</surname><given-names>A</given-names></name><name><surname>Sanders</surname><given-names>DW</given-names></name><name><surname>Diamond</surname><given-names>MI</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Gentleman</surname><given-names>SM</given-names></name><name><surname>Mordes</surname><given-names>DA</given-names></name><name><surname>S&#x000fc;dhof</surname><given-names>TC</given-names></name><name><surname>Giles</surname><given-names>K</given-names></name><name><surname>Prusiner</surname><given-names>SB</given-names></name></person-group>
<year>2015</year>
<article-title>Propagation of prions causing synucleinopathies in cultured cells</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>112</volume>
<fpage>E4949</fpage>
<lpage>E4958</lpage>
<pub-id pub-id-type="pmid">26286986</pub-id></element-citation></ref><ref id="r153"><label>153</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Postuma</surname><given-names>RB</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Bloem</surname><given-names>BR</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Joseph</surname><given-names>L</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Liepelt-Scarfone</surname><given-names>I</given-names></name><name><surname>Litvan</surname><given-names>I</given-names></name><name><surname>Marek</surname><given-names>K</given-names></name><name><surname>Obeso</surname><given-names>J</given-names></name><name><surname>Oertel</surname><given-names>W</given-names></name><name><surname>Olanow</surname><given-names>CW</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Stern</surname><given-names>M</given-names></name><name><surname>Deuschl</surname><given-names>G</given-names></name></person-group>
<year>2015</year>
<article-title>MDS research criteria for prodromal Parkinson&#x02019;s disease</article-title>
<source>Mov Disord</source>
<volume>30</volume>
<fpage>1600</fpage>
<lpage>1611</lpage>
<pub-id pub-id-type="pmid">26474317</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="jpd-5-4-jpd150685-g001" orientation="portrait" position="float"><label>Fig.1</label><caption><p>Midbrain / substantia nigra (SN) imaging with magnetic resonance imaging (MRI) and Transcranial sonography (TCS). A: Susceptibility weighted (SWI) MRI image of a healthy control (HC) at the left column, demonstrating the magnified dorsolateral nigral hyperintensity within the right SN. White arrows mark the dorsolateral nigral hyperintensity in the survey as well as in the magnified illustration. The right column show SWI images of a patient with Parkinson&#x02019;s disease (PD), demonstrating the absence of the dorsolateral nigral hyperintensity. B: TCS images of mesencaphalic scanning planes showing typically butterfly-shaped mesencephalic brainstems from a HC with a normal midbrain echogenicity in the upper images. A PD patient with an enlarged midbrain echogenicity at the area of the SN (SN-hyperechogenicity) is shown in the lower images.</p></caption><graphic xlink:href="jpd-5-4-jpd150685-g001"/></fig><table-wrap id="jpd-5-4-jpd150685-t001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Conceptual stages of Parkinson&#x02019;s disease</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="justify" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Phases of PD</td><td rowspan="1" colspan="1">Clinical status</td><td rowspan="1" colspan="1">Pathology</td><td rowspan="1" colspan="1">Comments</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Phase 1 - preclinical</td><td rowspan="1" colspan="1">No clinical signs or symptoms</td><td rowspan="1" colspan="1">PD-specific pathology assumed to be present</td><td rowspan="1" colspan="1">Supported by biomarkers (genetic, molecular, and/or imaging)</td></tr><tr><td rowspan="1" colspan="1">Phase 2 - prodromal</td><td rowspan="1" colspan="1">Early nonmotor symptoms&#x000b1;early subtle motor symptoms</td><td rowspan="1" colspan="1">Extranigral PD pathology (Braak stages 1 and 2)&#x000b1;nigral PD pathology (&#x0003c;40&#x02013;60% cell loss; Braak Stage 3)</td><td rowspan="1" colspan="1">Criteria yet to be defined based on clinical motor and nonmotor markers and nonclinical biomarkers. Two levels of certainty have been proposed [<xref rid="r19" ref-type="bibr">19</xref>]: Probable prodromal PD (high likelihood, e.g., &#x0003e;80% ; sufficiently certain for neuroprotective trials) and possible prodromal PD (lower, but still substantial likelihood, e.g., 30% &#x02013;80%)</td></tr><tr><td rowspan="1" colspan="1">Phase 3 - motor</td><td rowspan="1" colspan="1">Classical motor manifestations are present</td><td rowspan="1" colspan="1">Nigral PD pathology (&#x0003e;40&#x02013;60% cell loss; Braak stages 3 to 6)</td><td rowspan="1" colspan="1">Current clinical diagnostic criteria based on motor syndrome are met;&#x000b1;a variety on nonmotor symptoms may be present due to the extension of PD pathology</td></tr></tbody></table><table-wrap-foot><p>Modified from Stern et al. 2012 [<xref rid="r18" ref-type="bibr">18</xref>].</p></table-wrap-foot></table-wrap><table-wrap id="jpd-5-4-jpd150685-t002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Nonmotor symptoms in prodromal PD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Nonmotor<break/>&#x000a0;&#x000a0;&#x000a0;symptom</td><td rowspan="1" colspan="1">May occur prior<break/>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;to motor symptoms</td><td rowspan="1" colspan="1">Timespan before<break/>&#x000a0;&#x000a0;&#x000a0;motor onset</td><td rowspan="1" colspan="1">Sensitivity for<break/>&#x000a0;&#x000a0;&#x000a0;future PD</td><td rowspan="1" colspan="1">Specificity for<break/>&#x000a0;&#x000a0;&#x000a0;future PD</td><td rowspan="1" colspan="1">Reference</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>Sensory symptoms</italic>
</td></tr><tr><td rowspan="1" colspan="1">Hyposmia</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">Medium (up to</td><td rowspan="1" colspan="1">High (&#x0003e;80% PD</td><td rowspan="1" colspan="1">Low (&#x0003e;30% of elderly</td><td rowspan="1" colspan="1">[<xref rid="r7" ref-type="bibr">7, 9, 16, 17, 49</xref>]</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;5&#x02013;10 years)</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;patients affected)</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;have hyposmia)</td></tr><tr><td rowspan="1" colspan="1">Visual abnormalities</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">Unknown (in RBD up to 10 years)</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">[<xref rid="r14" ref-type="bibr">14, 50</xref>]</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;(e.g. reduced colour vision)</td></tr><tr><td rowspan="1" colspan="1">Pain</td><td rowspan="1" colspan="1">+/-</td></tr><tr><td rowspan="1" colspan="1">
<italic>Neuropsychiatric symptoms</italic>
</td></tr><tr><td rowspan="1" colspan="1">Depression and anxiety</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">Medium (up to 10 years)</td><td rowspan="1" colspan="1">Low (30&#x02013;40% </td><td rowspan="1" colspan="1">Low (common in the</td><td rowspan="1" colspan="1">[<xref rid="r7" ref-type="bibr">7, 8, 12, 13</xref>]</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;of PD patients affected)</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;elderly population)</td></tr><tr><td rowspan="1" colspan="1">Anhedonia and apathy</td><td rowspan="1" colspan="1">+/-</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">[<xref rid="r7" ref-type="bibr">7</xref>]</td></tr><tr><td rowspan="1" colspan="1">Frontal executive dysfunction</td><td rowspan="1" colspan="1">+/-</td></tr><tr><td rowspan="1" colspan="1">
<italic>Behavioural symptoms</italic>
</td></tr><tr><td rowspan="1" colspan="1">Quitting smoking</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">Long (mean 10 years)</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">[<xref rid="r51" ref-type="bibr">51, 52</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<italic>Autonomic dysfunction</italic>
</td></tr><tr><td rowspan="1" colspan="1">Constipation</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">Long (potentially more</td><td rowspan="1" colspan="1">Moderate (30&#x02013;60% </td><td rowspan="1" colspan="1">Low (common in the</td><td rowspan="1" colspan="1">[<xref rid="r7" ref-type="bibr">7&#x02013;11, 53</xref>]</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;than 10&#x02013;20 years)</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;of PD patients affected)</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;elderly population)</td></tr><tr><td rowspan="1" colspan="1">Orthostatic hypotension</td><td rowspan="1" colspan="1">+/-</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">[<xref rid="r8" ref-type="bibr">8</xref>]</td></tr><tr><td rowspan="1" colspan="1">Urogenital dysfunction</td><td rowspan="1" colspan="1">+/-</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">[<xref rid="r8" ref-type="bibr">8</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<italic>Sleep disorders</italic>
</td></tr><tr><td rowspan="1" colspan="1">RBD</td><td rowspan="1" colspan="1">++</td><td rowspan="1" colspan="1">Long (potentially more</td><td rowspan="1" colspan="1">Low to moderate (30&#x02013;50% </td><td rowspan="1" colspan="1">High (&#x0003e;80% of idiopathic</td><td rowspan="1" colspan="1">[<xref rid="r14" ref-type="bibr">14, 15, 54</xref>]</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;than 10&#x02013;20 years)</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;of PD patients affected)</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;RBD patients will develop</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;Lewy-body disorders)</td></tr><tr><td rowspan="1" colspan="1">Excessive daytime somnolence</td><td rowspan="1" colspan="1">+</td><td rowspan="1" colspan="1">Medium (up to 5&#x02013;10 years)</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">Unknown</td><td rowspan="1" colspan="1">[<xref rid="r7" ref-type="bibr">7, 55</xref>]</td></tr><tr><td rowspan="1" colspan="1">Sleep fragmentation and insomnia</td><td rowspan="1" colspan="1">+/-</td></tr><tr><td rowspan="1" colspan="1">PLMS/RLS</td><td rowspan="1" colspan="1">+/-</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: PD, Parkinson&#x02019;s disease; PLMS, periodic limb movements during sleep; RBD, rapid eye 
movement sleep behavior disorder; RLS, restless legs syndrome. ++&#x0200a;=&#x0200a;robust evidence from more than one prospective 
population-based or cohort study, +&#x0200a;=&#x0200a;evidence from one prospective population-based or cohort study or more than 
one retrospective population-based or cohort study, +/-&#x0200a;=&#x0200a;no evidence from population based or cohort studies, but 
respective nonmotor symptom is frequently seen in early PD [<xref rid="r43" ref-type="bibr">43&#x02013;45</xref>].</p></table-wrap-foot></table-wrap><table-wrap id="jpd-5-4-jpd150685-t003" orientation="portrait" position="float"><label>Table 3</label><caption><p>Parkinson&#x02019;s disease risk genes &#x02013;evidence from genome genome-wide association studies</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="justify" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Study</td><td rowspan="1" colspan="1">Design</td><td rowspan="1" colspan="1">Subjects</td><td rowspan="1" colspan="1">Results</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Nalls et al. 2011 [<xref rid="r101" ref-type="bibr">101</xref>]</td><td rowspan="1" colspan="1">Meta-analysis from 5 GWAS (USA &#x00026;Europe)</td><td rowspan="1" colspan="1">Discovery set: 5,333 PD and 12,019 controls; Replication set: 7,053 PD and 9,007 controls</td><td rowspan="1" colspan="1">&#x02022;Previously identified loci confirmed: MAPT, SNCA, HLA-DRB5, BST1, GAK and LRRK2</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02022;Newly identified loci: ACMSD, STK39, MCCC1/LAMP3, SYT11, and CCDC62/HIP1R</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02022;Odds ratio of 2.5 (95% CI 2.2&#x02013;2.8) in the highest versus the lowest quintile of disease risk</td></tr><tr><td rowspan="1" colspan="1">Pankratz et al. 2012 [<xref rid="r106" ref-type="bibr">106</xref>]</td><td rowspan="1" colspan="1">Meta-analysis from 5 GWAS (USA)</td><td rowspan="1" colspan="1">Discovery set: 4,238 PD and 4,239 controls; Replication set: 3,738 PD and 2,111 controls</td><td rowspan="1" colspan="1">&#x02022;Association with SNCA, MAPT, GAK/DGKQ, GBA and the HLA region confirmed</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02022;Novel locus RIT2</td></tr><tr><td rowspan="1" colspan="1">Lill et al. 2012 [<xref rid="r103" ref-type="bibr">103</xref>]</td><td rowspan="1" colspan="1">Meta-analysis from GWAS and PD association studies (literature screen)</td><td rowspan="1" colspan="1">Up to 16,452 PD and 48,810 controls (from 828 studies)</td><td rowspan="1" colspan="1">&#x02022;Association with BST1, CCDC62/HIP1R, DGKQ/GAK, GBA, LRRK2, MAPT, MCCC1/LAMP3, PARK16, SNCA, STK39, and SYT11/RAB25</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02022;Novel locus ITGA8</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02022;Results freely available on: <ext-link ext-link-type="uri" xlink:href="www.PDGene.org">www.PDGene.org</ext-link>
</td></tr><tr><td rowspan="1" colspan="1">Nalls et al. 2014 [<xref rid="r102" ref-type="bibr">102</xref>]</td><td rowspan="1" colspan="1">Meta-analysis from multiple GWAS in USA and Eurpoe</td><td rowspan="1" colspan="1">Discovery set: 13,708 cases and 95,282 controls; Replication set: 5,353 cases and 5,551 controls</td><td rowspan="1" colspan="1">&#x02022;Of the 32 SNPs tested in the replication set (26 loci identified in the discovery phase and 6 previously reported loci) 24 were replicated including 6 newly identified loci</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02022;4 loci (GBA, GAK/DGKQ, SNCA and the HLA region) contained a secondary independent risk variant</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02022;Odds ratio of 3.3 (95% CI 2.6&#x02013;4.3) in the highest versus the lowest quintile of disease risk</td></tr></tbody></table></table-wrap><table-wrap id="jpd-5-4-jpd150685-t004" orientation="portrait" position="float"><label>Table 4</label><caption><p>Selection of studies assessing the potential of a-synuclein- and DJ1-based CSF markers for detecting PD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead valign="top"><tr><td rowspan="1" colspan="1">Marker/Study</td><td rowspan="1" colspan="1">Change</td><td rowspan="1" colspan="1">Sensitivity</td><td rowspan="1" colspan="1">Specificity</td><td rowspan="1" colspan="1">Comments</td><td rowspan="1" colspan="1">References</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;(REF)</td><td rowspan="1" colspan="1">in PD</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Total &#x003b1;-Syn</td><td rowspan="1" colspan="1">&#x02193;</td><td rowspan="1" colspan="1">71% &#x02013;100% </td><td rowspan="1" colspan="1">38% &#x02013;58% </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">[<xref rid="r110" ref-type="bibr">110, 124&#x02013;128</xref>]</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02193;</td><td rowspan="1" colspan="1">91% </td><td rowspan="1" colspan="1">25% </td><td rowspan="1" colspan="1">Studies in early drug-naive PD</td><td rowspan="1" colspan="1">[<xref rid="r110" ref-type="bibr">110, 128</xref>]</td></tr><tr><td rowspan="1" colspan="1">Phosphorylated</td><td rowspan="1" colspan="1">&#x02191;</td><td rowspan="1" colspan="1">61% </td><td rowspan="1" colspan="1">80% </td><td rowspan="1" colspan="1">For combined phosphorylated and total</td><td rowspan="1" colspan="1">[<xref rid="r129" ref-type="bibr">129</xref>]</td></tr><tr><td rowspan="1" colspan="1">&#x003b1;-Syn</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">80% </td><td rowspan="1" colspan="1">64% </td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x003b1;-Syn using two different cut-off values</td></tr><tr><td rowspan="1" colspan="1">
&#x003b1;-Syn</td><td rowspan="1" colspan="1">&#x02191;</td><td rowspan="1" colspan="1">75% </td><td rowspan="1" colspan="1">88% </td><td rowspan="1" colspan="1">
&#x003b1;-Syn oligomers alone</td><td rowspan="1" colspan="1">[<xref rid="r130" ref-type="bibr">130</xref>]</td></tr><tr><td rowspan="1" colspan="1">Oligomers</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">89% </td><td rowspan="1" colspan="1">91% </td><td rowspan="1" colspan="1">Ratio to total &#x003b1;-Syn</td></tr><tr><td rowspan="1" colspan="1">DJ1</td><td rowspan="1" colspan="1">&#x02193;</td><td rowspan="1" colspan="1">90% &#x02013;97% </td><td rowspan="1" colspan="1">50% &#x02013;70% </td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">[<xref rid="r124" ref-type="bibr">124, 125</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>